Chapter 25

Laboratory Services

25.1 Enrollment .................................................................................................................. 25-2
  25.1.1 Clinical Laboratory Improvement Amendments (CLIA) of 1988 ...................... 25-3
    25.1.1.1 Waiver and Physician-Performed Microscopy Procedure (PPMP) Certificates 25-3
25.2 Benefits, Limitations, and Authorization Requirements ........................................... 25-4
  25.2.1 Hospital Laboratory Services .............................................................................. 25-4
  25.2.2 Independent Laboratory Services ........................................................................ 25-4
  25.2.3 Physician-Owned Laboratory Services .............................................................. 25-5
    25.2.3.1 Other Physician Laboratory-Related Services ............................................. 25-5
  25.2.4 Clinical Pathology Services .................................................................................. 25-5
  25.2.5 Other Laboratory Procedures .............................................................................. 25-6
    25.2.5.1 Drug Testing and Therapeutic Drug Assays ............................................... 25-6
    25.2.5.2 Cytogenetics Testing .................................................................................... 25-7
    25.2.5.3 Genetic Testing for Colorectal Cancer ......................................................... 25-29
    25.2.5.4 Genetic Testing for Hereditary Breast and Ovarian Cancers ................. 25-31
  25.2.6 Cytopathology of Vaginal, Cervical, and Uterine Sites ........................................ 25-33
  25.2.7 Cytopathology Studies Other Than Vaginal, Cervical, or Uterine .................... 25-33
  25.2.8 Evocative and Suppression Testing ..................................................................... 25-34
  25.2.9 Helicobacter pylori (H. pylori) ............................................................................. 25-34
  25.2.10 Hematology and Coagulation .......................................................................... 25-35
  25.2.11 Microbiology ..................................................................................................... 25-36
  25.2.12 Human Immunodeficiency Virus (HIV) Drug Resistance Testing ............... 25-36
  25.2.13 Organ or Disease-Oriented Panels .................................................................. 25-37
  25.2.14 Urinalysis and Chemistry ............................................................................... 25-37
  25.2.15 Other Laboratory Services .............................................................................. 25-39
  25.2.16 Repeated Procedures ....................................................................................... 25-39
    25.2.16.1 Modifier 91 ................................................................................................. 25-39
  25.2.17 Receiving Labs and Lab Handling Fees ............................................................. 25-39
25.3 Claims Information.................................................................................................... 25-40
  25.3.1 Modifiers To Use When Billing Laboratory Procedures .................................. 25-40
25.4 Reimbursement ........................................................................................................ 25-41
  25.4.1 Clinical Laboratory Fee Schedule ...................................................................... 25-41
  25.4.2 One-day Payment Window Reimbursement Guidelines .................................. 25-41
25.5 TMHP-CSHCN Services Program Contact Center .................................................... 25-41

CPT only copyright 2016 American Medical Association. All rights reserved.
25.1 Enrollment

To enroll in the CSHCN Services Program, laboratories must be actively enrolled in Texas Medicaid, have a valid Provider Agreement with the CSHCN Services Program, have completed the CSHCN Services Program enrollment process, be certified according to the Clinical Laboratory Improvement Amendments (CLIA) of 1988, and comply with all applicable state laws and requirements. Out-of-state laboratory providers must meet all of these conditions and be located in the United States within 50 miles of the Texas state border.

The following laboratories are eligible for enrollment in the CSHCN Services Program:

• A physician’s office
  • Meets staff, equipment, and testing capability standards for certification by the Department of State Health Services (DSHS)
  • Medicare-certified and enrolled as a Medicaid provider
  • Providers must also submit a current copy of their permit or license and a copy of the approval letter from DSHS

Note: If a physician performs more than 100 laboratory tests per year for other providers in their laboratory, the laboratory must be certified by Medicare, and the provider must enroll as an independent laboratory with TMHP.

• A hospital laboratory for inpatient, outpatient, and nonpatient client claims (a hospital nonpatient is one who is not registered as an inpatient or an outpatient but whose laboratory services are performed by the hospital laboratory)
  • Meets staff, equipment, and testing capability standards for certification by the Department of State Health Services (DSHS)
  • Medicare-certified and enrolled as a Medicaid provider
  • Providers must also submit a current copy of their permit or license and a copy of the approval letter from DSHS

• An independent (freestanding) laboratory
  • An independent (freestanding) laboratory enrolled in the CSHCN Services Program is defined as a facility that meets all of the following criteria:
    • Facility independent from a physician’s office, ASC, or hospital
    • Meets staff, equipment, and testing capability standards for certification by the Department of State Health Services (DSHS)
    • Medicare-certified and enrolled as a Medicaid provider
    • Providers must also submit a current copy of their permit or license and a copy of the approval letter from DSHS

Important: CSHCN Services Program providers are responsible for knowing, understanding, and complying with the laws, administrative rules, and policies of the CSHCN Services Program and Texas Medicaid.

By enrolling in the CSHCN Services Program, providers are charged not only with knowledge of the adopted CSHCN Services Program agency rules published in Title 25 Texas Administrative Code (TAC), but also with knowledge of the adopted Medicaid agency rules published in 1 TAC, Part 15, and specifically including the fraud and abuse provisions contained in Chapter 371.

CSHCN Services Program providers also are required to comply with all applicable laws, administrative rules, and policies that apply to their professions or to their facilities. Specifically, it is a violation of program rules when a provider fails to provide health-care services or items to recipients in accordance with accepted medical community standards and standards that govern occupations, as explained in 1 TAC §371.1659 for Medicaid providers, which also applies to CSHCN Services Program providers as set forth in 25 TAC §38.6(b)(1). Accordingly, CSHCN Services Program providers can be subject to sanctions for failure to deliver, at all times, health-care items and services to recipients in full accordance with all applicable licensure and certification requirements. These include, without limitation, requirements...
related to documentation and record maintenance, such that a CSHCN Services Program provider can be subject to sanctions for failure to create and maintain all records required by his or her profession, as well as those required by the CSHCN Services Program and Texas Medicaid.

Refer to: The CMS website at www.cms.gov/CLIA/10_Categorization_of_Tests.asp for information about procedure codes and modifier QW requirements. The CSHCN Services Program follows the Medicare categorization of tests for CLIA certificate-holders. Section 2.1, “Provider Enrollment,” on page 2-2 for more detailed information about CSHCN Services Program provider enrollment procedures.

25.1.1 Clinical Laboratory Improvement Amendments (CLIA) of 1988

To be eligible for reimbursement by the CSHCN Services Program, all providers performing laboratory tests must:

• Enroll with the Centers for Medicare & Medicaid Services (CMS).
• Receive a CLIA registration and certification number by contacting DSHS at 1-512-834-6792 or access CLIA information at www.dshs.state.tx.us/facilities/clia.aspx or at www.cms.hhs.gov/clia.

Submit CLIA applications to the following address:

Texas Department of State Health Services
Patient Quality Care, MC-1979/E 30000
1100 West 49th Street
Austin, TX 78756

Notify TMHP of the assigned CLIA number by fax at 1-512-514-4214 or by mail at the following address:

Texas Medicaid & Healthcare Partnership
Attn: Provider Enrollment
PO Box 200795
Austin, TX 78720–0795

CMS implemented CLIA. The CLIA regulations were published in the February 28, 1992, Federal Register and have been amended several times since.

Copies of the CLIA rules and regulations are located at the CMS website at www.cms.hhs.gov. These regulations concern all laboratory testing used for the assessment of human health or the diagnosis, prevention, or treatment of disease. CLIA regulations set standards designed to improve quality in all laboratory testing and include specifications for quality control (QC), quality assurance (QA), patient test management, personnel, and proficiency testing. Under CLIA 88, all clinical laboratories (including those located in physician's offices), regardless of location, size, or type of laboratory must meet standards based on the complexity of the test(s) they perform.

Important: The CSHCN Services Program monitors claims submitted by clinical laboratories for CLIA numbers. Claims submitted for laboratory services are denied if there is not a CLIA number on file with the CSHCN Services Program.

Refer to: The CMS website at www.cms.gov/CLIA/10_Categorization_of_Tests.asp for information about procedure codes and modifier QW requirements. The CSHCN Services Program follows the Medicare categorization of tests for CLIA certificate-holders.

25.1.1.1 Waiver and Physician-Performed Microscopy Procedure (PPMP) Certificates

Providers are responsible for practicing within the limits of their certificates and maintaining awareness of the most current information regarding enforcement of CLIA provisions.

Note: Providers may refer to the CMS website at www.cms.gov/CLIA/10_Categorization_of_Tests.asp for a list of waived test and provider-performed microscopy procedures (PPMP) procedure codes.

CSHCN Services Program bills must accurately reflect only those services authorized by CLIA regulations.
25.2 Benefits, Limitations, and Authorization Requirements

Authorization is not required for laboratory services.

The CSHCN Services Program may reimburse the following laboratories for services when the laboratory is certified according to the CLIA regulations and enrolled in the CSHCN Services Program:

- A hospital laboratory for outpatient and nonpatient client claims
- A physician’s office
- An independent laboratory

Providers must bill the most specific diagnosis and procedure codes that describe the services provided.

Laboratory tests generally performed as a panel and performed on the same day by the same provider, must be billed as a panel, regardless of the method used to perform the tests (automated or manual).

The CSHCN Services Program pays only the amount allowed for the total component for the same procedure, same client, same date of service, and any provider.

- Providers who perform both the technical service and interpretation must bill for the total component.
- Providers who perform only the technical service must bill for the technical component.
- Providers who perform only the interpretation must bill for the interpretation component.

Claims filed in excess of the amount allowed for the total component for the same procedure, same dates of service, same client, any provider, are denied.

Claims are paid based on the order in which they are received. For example, if a claim is received for the total component, and if payment has been made for the technical and interpretation component for the same procedure, same dates of service, same client, from any provider, the claim for the total component is denied as previously paid to another provider. The same is true if a total component is paid and subsequent claims are received for the individual components.

25.2.1 Hospital Laboratory Services

Hospital laboratory services are a benefit for inpatient, outpatient, and nonpatient clients. A hospital nonpatient is one who is not registered as an inpatient or an outpatient but whose laboratory services are performed by the hospital laboratory.

Outpatient and nonpatient claims for laboratory services must reflect only tests actually performed by the hospital laboratory. However, hospital laboratories may bill for all of the tests performed on a specimen even if a portion of the tests are done by another laboratory on referral from the hospital submitting the claim. If the specimen is collected by venipuncture or catheterization, hospitals may bill procedure code 99001 for collecting and forwarding a specimen to a receiving laboratory. Only one handling fee may be charged per day, per client, unless specimens are sent to two or more laboratories.

In order to bill a handling fee, the receiving laboratory’s name and address and unique Texas provider identifier (TPI) number must be included on the claim in Blocks 17 and 17B.

In order to bill nonpatient claims for laboratory services, the complete name and address and unique TPI of the attending, ordering, designated, or performing (freestanding ASCs only) provider must be included on the claim in Blocks 17 and 17B.

25.2.2 Independent Laboratory Services

Independent laboratories that provide laboratory tests to clients registered as hospital inpatients or hospital outpatients are not directly reimbursed. Reimbursement must be obtained from the hospital.

An independent laboratory that forwards a specimen to another laboratory without performing any tests on that specimen may not bill for laboratory tests. An independent laboratory may bill the CSHCN Services Program for tests referred to another laboratory (independent or hospital).
only if the independent laboratory performs at least one test and forwards a portion of the same specimen to another laboratory to have one or more tests performed. In this instance, the referring laboratory may bill for tests it performs and all tests the receiving laboratory performs on the specimen. In both instances, an independent laboratory that forwards a specimen to another laboratory may bill a handling fee (procedure code 99001) for collection and forwarding the specimen if the specimen is collected by venipuncture or catheterization.

In order to bill a handling fee, the receiving laboratory’s name and address and unique TPI number must be included on the claim in Blocks 17 and 17B.

The CSHCN Services Program covers professional and technical services that an independent laboratory is certified by Medicare to perform.

25.2.3 Physician-Owned Laboratory Services

The CSHCN Services Program reimburses laboratory services ordered by a physician and provided under the provider’s personal supervision in a setting other than an inpatient or outpatient hospital.

25.2.3.1 Other Physician Laboratory-Related Services

Physicians may only bill for those laboratory tests that are actually performed in their offices. Clinical laboratory services performed in a physician’s office may be reimbursed at 60 percent of the prevailing charge levels. A laboratory handling fee (procedure code 99000) may be billed if the specimen is obtained by venipuncture or catheterization and sent to an outside laboratory. Only one lab handling fee per day, per client, may be billed, unless multiple specimens are obtained and sent to different laboratories.

In order to bill a handling fee, the receiving laboratory’s name and address and unique TPI number must be included on the claim in Blocks 17 and 17B.

Laboratory services must be documented in clients’ medical records as medically necessary and reference an appropriate diagnosis.

Laboratory tests generally performed as a panel (chemistries, complete blood counts [CBCs], or urinalyses [UAs]) and performed on the same day by the same provider must be billed as a panel regardless of the method used to perform the test.

Interpretation of laboratory tests for the physician’s patients in the hospital, office, or emergency rooms are considered part of the physician’s professional services and should not be billed separately.

25.2.4 Clinical Pathology Services

Clinical pathology consultations are a benefit when performed by a clinical pathologist or geneticist. A geneticist may submit claims for procedure codes 80500 and 80502 using their physician provider identifier.

Independent laboratories may submit claims for procedure codes 80500 and 80502 when services are performed in the independent laboratory setting.

Routine conversations between a consultant and an attending physician about test orders or results are not considered consultations.

The service does not qualify as a consultation if the information could ordinarily be furnished by a non-physician laboratory specialist.

Claims for clinical pathology consultations must be submitted with the following documentation:

- The name and address, or the CSHCN Services Program provider identifier for the physician requesting the consultation, must be included on the claim. The NPI of the physician requesting the consultation should also be included, if known.
- A copy of the written narrative report describing the consultation findings.
• Documented interaction that clearly outlines that the consultant interpreted the test results and made specific recommendations to the ordering physician.

**Important:** If the claim does not include all of this information, the clinical pathology consultation will be denied.

### 25.2.5 Other Laboratory Procedures

#### Procedure Codes

<table>
<thead>
<tr>
<th>Procedure Codes</th>
<th>1 per lifetime</th>
</tr>
</thead>
<tbody>
<tr>
<td>S3840</td>
<td>S3841</td>
</tr>
<tr>
<td>S3842</td>
<td>S3846</td>
</tr>
</tbody>
</table>

### 25.2.5.1 Drug Testing and Therapeutic Drug Assays

The following procedure codes for drug testing and therapeutic drug assays are benefits of the CSHCN Services Program:

#### Procedure Codes

**Drug Testing**

- 80305
- 80306
- 80307
- 80320
- 80321
- 80322
- 80323
- 80324
- 80325
- 80326
- 80327
- 80328
- 80329
- 80330
- 80331
- 80332
- 80333
- 80334
- 80335
- 80336
- 80337
- 80338
- 80339
- 80340
- 80341
- 80342
- 80343
- 80344
- 80345
- 80346
- 80347
- 80348
- 80349
- 80350
- 80351
- 80352
- 80353
- 80354
- 80355
- 80356
- 80357
- 80358
- 80359
- 80360
- 80361
- 80362
- 80363
- 80364
- 80365
- 80366
- 80367
- 80368
- 80369
- 80370
- 80371
- 80372
- 80373
- 80374
- 80375
- 80376
- 80377
- G0480
- G0481
- G0482
- G0483
- G0659

**Therapeutic Drug Assays**

- 80150
- 80155
- 80156
- 80157
- 80158
- 80159
- 80162
- 80163
- 80164
- 80165
- 80168
- 80169
- 80170
- 80171
- 80173
- 80175
- 80176
- 80177
- 80178
- 80180
- 80183
- 80184
- 80185
- 80186
- 80188
- 80190
- 80192
- 80194
- 80195
- 80197
- 80198
- 80199
- 80200
- 80201
- 80202
- 80203
- 80299

*CLIA Waved test*

**Note:** The procedure codes above do not require prior authorization.

Procedure codes G0480, G0481, G0482, G0483, and G0659 are limited to once per day by any provider.

The following CPT drug assay procedure codes will deny when billed on the same date of service, by the same provider with the corresponding HCPCS drug assay procedure codes identified by an "X" in the following table:

#### CPT Drug Assay Procedure Codes to HCPCS Procedure Codes limitations

<table>
<thead>
<tr>
<th>Procedure Codes</th>
<th>G0480</th>
<th>G0481</th>
<th>G0482</th>
<th>G0483</th>
<th>G0659</th>
</tr>
</thead>
<tbody>
<tr>
<td>80305</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80306</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>80307</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>80320</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>80321</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80323</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

* - The "8000" CPT procedure code will be denied if billed with the HCPCS "G" procedure code indicated with an "X".
### CPT Drug Assay Procedure Codes to HCPCS Procedure Codes limitations

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Quantity Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>80324</td>
<td>X</td>
</tr>
<tr>
<td>80325</td>
<td>X</td>
</tr>
<tr>
<td>80326</td>
<td>X</td>
</tr>
<tr>
<td>80327</td>
<td>X</td>
</tr>
<tr>
<td>80328</td>
<td>X</td>
</tr>
<tr>
<td>80329</td>
<td>X</td>
</tr>
<tr>
<td>80330</td>
<td>X</td>
</tr>
<tr>
<td>80332</td>
<td>X</td>
</tr>
<tr>
<td>80333</td>
<td>X</td>
</tr>
<tr>
<td>80335</td>
<td>X</td>
</tr>
<tr>
<td>80336</td>
<td>X</td>
</tr>
<tr>
<td>80337</td>
<td>X</td>
</tr>
<tr>
<td>80338</td>
<td>X</td>
</tr>
<tr>
<td>80339</td>
<td>X</td>
</tr>
<tr>
<td>80342</td>
<td>X</td>
</tr>
<tr>
<td>80345</td>
<td>X</td>
</tr>
<tr>
<td>80358</td>
<td>X</td>
</tr>
<tr>
<td>80363</td>
<td>X</td>
</tr>
<tr>
<td>80365</td>
<td>X</td>
</tr>
<tr>
<td>80366</td>
<td>X</td>
</tr>
<tr>
<td>80369</td>
<td>X</td>
</tr>
<tr>
<td>80370</td>
<td>X</td>
</tr>
<tr>
<td>80375</td>
<td>X</td>
</tr>
<tr>
<td>80377</td>
<td>X</td>
</tr>
</tbody>
</table>

X - The "8000" CPT procedure code will be denied if billed with the HCPCS "G" procedure code indicated with an "X".

### 25.2.5.2 Cytogenetics Testing

When billed with an appropriate diagnosis code, cytogenetics testing procedure codes have the following limitations:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Quantity Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue Culture</td>
<td></td>
</tr>
<tr>
<td>88230</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88233</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88235</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88237</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88239</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88240</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88241</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>Chromosome Analysis</td>
<td></td>
</tr>
<tr>
<td>88245</td>
<td>1 per day, any provider</td>
</tr>
<tr>
<td>88248</td>
<td>1 per day, any provider</td>
</tr>
</tbody>
</table>
Providers must bill procedure code 88291 for the interpretation and report of cytogenetics testing. Reimbursement for cytogenetics testing is limited to the following diagnosis codes:

<table>
<thead>
<tr>
<th>Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8280</td>
<td>Other types of follicular lymphoma, unspecified site</td>
</tr>
<tr>
<td>C8281</td>
<td>Other types of follicular lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8282</td>
<td>Other types of follicular lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8283</td>
<td>Other types of follicular lymphoma, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8284</td>
<td>Other types of follicular lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8285</td>
<td>Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8286</td>
<td>Other types of follicular lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8287</td>
<td>Other types of follicular lymphoma, spleen</td>
</tr>
<tr>
<td>C8288</td>
<td>Other types of follicular lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8289</td>
<td>Other types of follicular lymphoma, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8291</td>
<td>Follicular lymphoma, unspecified, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8292</td>
<td>Follicular lymphoma, unspecified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8293</td>
<td>Follicular lymphoma, unspecified, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8294</td>
<td>Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8295</td>
<td>Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8296</td>
<td>Follicular lymphoma, unspecified, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8297</td>
<td>Follicular lymphoma, unspecified, spleen</td>
</tr>
<tr>
<td>C8298</td>
<td>Follicular lymphoma, unspecified, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8299</td>
<td>Follicular lymphoma, unspecified, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8310</td>
<td>Mantle cell lymphoma, unspecified site</td>
</tr>
<tr>
<td>C8311</td>
<td>Mantle cell lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>C8312</td>
<td>Mantle cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8313</td>
<td>Mantle cell lymphoma, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8314</td>
<td>Mantle cell lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8315</td>
<td>Mantle cell lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8316</td>
<td>Mantle cell lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8317</td>
<td>Mantle cell lymphoma, spleen</td>
</tr>
<tr>
<td>C8318</td>
<td>Mantle cell lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8319</td>
<td>Mantle cell lymphoma, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8320</td>
<td>Other non-follicular lymphoma, unspecified site</td>
</tr>
<tr>
<td>C8321</td>
<td>Other non-follicular lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8322</td>
<td>Other non-follicular lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8323</td>
<td>Other non-follicular lymphoma, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8324</td>
<td>Other non-follicular lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8325</td>
<td>Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8326</td>
<td>Other non-follicular lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8327</td>
<td>Other non-follicular lymphoma, spleen</td>
</tr>
<tr>
<td>C8328</td>
<td>Other non-follicular lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8329</td>
<td>Other non-follicular lymphoma, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8440</td>
<td>Peripheral T-cell lymphoma, not classified, unspecified site</td>
</tr>
<tr>
<td>C8441</td>
<td>Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8442</td>
<td>Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8443</td>
<td>Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8444</td>
<td>Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8445</td>
<td>Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8446</td>
<td>Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8447</td>
<td>Peripheral T-cell lymphoma, not classified, spleen</td>
</tr>
<tr>
<td>C8448</td>
<td>Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8449</td>
<td>Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8461</td>
<td>Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8462</td>
<td>Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8463</td>
<td>Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8464</td>
<td>Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8465</td>
<td>Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8466</td>
<td>Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8467</td>
<td>Anaplastic large cell lymphoma, ALK-positive, spleen</td>
</tr>
<tr>
<td>C8468</td>
<td>Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>C8469</td>
<td>Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8471</td>
<td>Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8472</td>
<td>Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8473</td>
<td>Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C8474</td>
<td>Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8475</td>
<td>Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8476</td>
<td>Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8477</td>
<td>Anaplastic large cell lymphoma, ALK-negative, spleen</td>
</tr>
<tr>
<td>C8478</td>
<td>Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8479</td>
<td>Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C8581</td>
<td>Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C8582</td>
<td>Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C8584</td>
<td>Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C8585</td>
<td>Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C8586</td>
<td>Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C8587</td>
<td>Other specified types of non-Hodgkin lymphoma, spleen</td>
</tr>
<tr>
<td>C8588</td>
<td>Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C8589</td>
<td>Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites</td>
</tr>
<tr>
<td>C884</td>
<td>Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]</td>
</tr>
<tr>
<td>C888</td>
<td>Other malignant immunoproliferative diseases</td>
</tr>
<tr>
<td>C9012</td>
<td>Plasma cell leukemia in relapse</td>
</tr>
<tr>
<td>C9100</td>
<td>Acute lymphoblastic leukemia not having achieved remission</td>
</tr>
<tr>
<td>C9101</td>
<td>Acute lymphoblastic leukemia, in remission</td>
</tr>
<tr>
<td>C9102</td>
<td>Acute lymphoblastic leukemia, in relapse</td>
</tr>
<tr>
<td>C9110</td>
<td>Chronic lymphocytic leukemia of B-cell type not having achieved remission</td>
</tr>
<tr>
<td>C9111</td>
<td>Chronic lymphocytic leukemia of B-cell type in remission</td>
</tr>
<tr>
<td>C9112</td>
<td>Chronic lymphocytic leukemia of B-cell type in relapse</td>
</tr>
<tr>
<td>C9190</td>
<td>Lymphoid leukemia, unspecified not having achieved remission</td>
</tr>
<tr>
<td>C9191</td>
<td>Lymphoid leukemia, unspecified, in remission</td>
</tr>
<tr>
<td>C9192</td>
<td>Lymphoid leukemia, unspecified, in relapse</td>
</tr>
<tr>
<td>C91Z0</td>
<td>Other lymphoid leukemia not having achieved remission</td>
</tr>
<tr>
<td>C91Z1</td>
<td>Other lymphoid leukemia, in remission</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>C91Z2</td>
<td>Other lymphoid leukemia, in relapse</td>
</tr>
<tr>
<td>C9200</td>
<td>Acute myeloblastic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9201</td>
<td>Acute myeloblastic leukemia, in remission</td>
</tr>
<tr>
<td>C9202</td>
<td>Acute myeloblastic leukemia, in relapse</td>
</tr>
<tr>
<td>C9210</td>
<td>Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission</td>
</tr>
<tr>
<td>C9211</td>
<td>Chronic myeloid leukemia, BCR/ABL-positive, in remission</td>
</tr>
<tr>
<td>C9212</td>
<td>Chronic myeloid leukemia, BCR/ABL-positive, in relapse</td>
</tr>
<tr>
<td>C9220</td>
<td>Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission</td>
</tr>
<tr>
<td>C9221</td>
<td>Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission</td>
</tr>
<tr>
<td>C9222</td>
<td>Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse</td>
</tr>
<tr>
<td>C9230</td>
<td>Myeloid sarcoma, not having achieved remission</td>
</tr>
<tr>
<td>C9231</td>
<td>Myeloid sarcoma, in remission</td>
</tr>
<tr>
<td>C9232</td>
<td>Myeloid sarcoma, in relapse</td>
</tr>
<tr>
<td>C9240</td>
<td>Acute promyelocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9241</td>
<td>Acute promyelocytic leukemia, in remission</td>
</tr>
<tr>
<td>C9242</td>
<td>Acute promyelocytic leukemia, in relapse</td>
</tr>
<tr>
<td>C9250</td>
<td>Acute myelomonocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9251</td>
<td>Acute myelomonocytic leukemia, in remission</td>
</tr>
<tr>
<td>C9252</td>
<td>Acute myelomonocytic leukemia, in relapse</td>
</tr>
<tr>
<td>C9260</td>
<td>Acute myeloid leukemia with 11q23-abnormality not having achieved remission</td>
</tr>
<tr>
<td>C9261</td>
<td>Acute myeloid leukemia with 11q23-abnormality in remission</td>
</tr>
<tr>
<td>C9262</td>
<td>Acute myeloid leukemia with 11q23-abnormality in relapse</td>
</tr>
<tr>
<td>C9290</td>
<td>Myeloid leukemia, unspecified, not having achieved remission</td>
</tr>
<tr>
<td>C9291</td>
<td>Myeloid leukemia, unspecified in remission</td>
</tr>
<tr>
<td>C9292</td>
<td>Myeloid leukemia, unspecified in relapse</td>
</tr>
<tr>
<td>C92A0</td>
<td>Acute myeloid leukemia with multilineage dysplasia, not having achieved remission</td>
</tr>
<tr>
<td>C92A1</td>
<td>Acute myeloid leukemia with multilineage dysplasia, in remission</td>
</tr>
<tr>
<td>C92A2</td>
<td>Acute myeloid leukemia with multilineage dysplasia, in relapse</td>
</tr>
<tr>
<td>C92Z0</td>
<td>Other myeloid leukemia not having achieved remission</td>
</tr>
<tr>
<td>C92Z1</td>
<td>Other myeloid leukemia, in remission</td>
</tr>
<tr>
<td>C92Z2</td>
<td>Other myeloid leukemia, in relapse</td>
</tr>
<tr>
<td>C9300</td>
<td>Acute monoblastic/monocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9301</td>
<td>Acute monoblastic/monocytic leukemia, in remission</td>
</tr>
<tr>
<td>C9302</td>
<td>Acute monoblastic/monocytic leukemia, in relapse</td>
</tr>
<tr>
<td>C9310</td>
<td>Chronic myelomonocytic leukemia not having achieved remission</td>
</tr>
<tr>
<td>C9311</td>
<td>Chronic myelomonocytic leukemia, in remission</td>
</tr>
<tr>
<td>C9312</td>
<td>Chronic myelomonocytic leukemia, in relapse</td>
</tr>
<tr>
<td>C9330</td>
<td>Juvenile myelomonocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9331</td>
<td>Juvenile myelomonocytic leukemia, in remission</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------------------------</td>
</tr>
<tr>
<td>C9390</td>
<td>Monocytic leukemia, unspecified, not having achieved remission</td>
</tr>
<tr>
<td>C9391</td>
<td>Monocytic leukemia, unspecified in remission</td>
</tr>
<tr>
<td>C9392</td>
<td>Monocytic leukemia, unspecified in relapse</td>
</tr>
<tr>
<td>C93Z0</td>
<td>Other monocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C93Z1</td>
<td>Other monocytic leukemia, in remission</td>
</tr>
<tr>
<td>C93Z2</td>
<td>Other monocytic leukemia, in relapse</td>
</tr>
<tr>
<td>C9400</td>
<td>Acute erythroid leukemia, not having achieved remission</td>
</tr>
<tr>
<td>C9401</td>
<td>Acute erythroid leukemia, in remission</td>
</tr>
<tr>
<td>C9402</td>
<td>Acute erythroid leukemia, in relapse</td>
</tr>
<tr>
<td>C9420</td>
<td>Acute megakaryoblastic leukemia not having achieved remission</td>
</tr>
<tr>
<td>C9421</td>
<td>Acute megakaryoblastic leukemia, in remission</td>
</tr>
<tr>
<td>C9422</td>
<td>Acute megakaryoblastic leukemia, in relapse</td>
</tr>
<tr>
<td>C9430</td>
<td>Mast cell leukemia not having achieved remission</td>
</tr>
<tr>
<td>C9431</td>
<td>Mast cell leukemia, in remission</td>
</tr>
<tr>
<td>C9432</td>
<td>Mast cell leukemia, in relapse</td>
</tr>
<tr>
<td>C9480</td>
<td>Other specified leukemias not having achieved remission</td>
</tr>
<tr>
<td>C9481</td>
<td>Other specified leukemias, in remission</td>
</tr>
<tr>
<td>C9482</td>
<td>Other specified leukemias, in relapse</td>
</tr>
<tr>
<td>C9500</td>
<td>Acute leukemia of unspecified cell type not having achieved remission</td>
</tr>
<tr>
<td>C9501</td>
<td>Acute leukemia of unspecified cell type, in remission</td>
</tr>
<tr>
<td>C9502</td>
<td>Acute leukemia of unspecified cell type, in relapse</td>
</tr>
<tr>
<td>C9510</td>
<td>Chronic leukemia of unspecified cell type not having achieved remission</td>
</tr>
<tr>
<td>C9511</td>
<td>Chronic leukemia of unspecified cell type, in remission</td>
</tr>
<tr>
<td>C9512</td>
<td>Chronic leukemia of unspecified cell type, in relapse</td>
</tr>
<tr>
<td>C9590</td>
<td>Leukemia, unspecified not having achieved remission</td>
</tr>
<tr>
<td>C9591</td>
<td>Leukemia, unspecified, in remission</td>
</tr>
<tr>
<td>C9592</td>
<td>Leukemia, unspecified, in relapse</td>
</tr>
<tr>
<td>D45</td>
<td>Polycythemia vera</td>
</tr>
<tr>
<td>D821</td>
<td>Di George's syndrome</td>
</tr>
<tr>
<td>E230</td>
<td>Hypopituitarism</td>
</tr>
<tr>
<td>E291</td>
<td>Testicular hypofunction</td>
</tr>
<tr>
<td>E300</td>
<td>Delayed puberty</td>
</tr>
<tr>
<td>E343</td>
<td>Short stature due to endocrine disorder</td>
</tr>
<tr>
<td>E83110</td>
<td>Hereditary hemochromatosis</td>
</tr>
<tr>
<td>E8359</td>
<td>Other disorders of calcium metabolism</td>
</tr>
<tr>
<td>F70</td>
<td>Mild intellectual disabilities</td>
</tr>
<tr>
<td>F71</td>
<td>Moderate intellectual disabilities</td>
</tr>
<tr>
<td>F72</td>
<td>Severe intellectual disabilities</td>
</tr>
<tr>
<td>F73</td>
<td>Profound intellectual disabilities</td>
</tr>
<tr>
<td>F78</td>
<td>Other intellectual disabilities</td>
</tr>
<tr>
<td>F800</td>
<td>Phonological disorder</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F801</td>
<td>Expressive language disorder</td>
</tr>
<tr>
<td>F802</td>
<td>Mixed receptive-expressive language disorder</td>
</tr>
<tr>
<td>F804</td>
<td>Speech and language development delay due to hearing loss</td>
</tr>
<tr>
<td>F8089</td>
<td>Other developmental disorders of speech and language</td>
</tr>
<tr>
<td>F810</td>
<td>Specific reading disorder</td>
</tr>
<tr>
<td>F812</td>
<td>Mathematics disorder</td>
</tr>
<tr>
<td>F8181</td>
<td>Disorder of written expression</td>
</tr>
<tr>
<td>F8189</td>
<td>Other developmental disorders of scholastic skills</td>
</tr>
<tr>
<td>F819</td>
<td>Developmental disorder of scholastic skills, unspecified</td>
</tr>
<tr>
<td>F82</td>
<td>Specific developmental disorder of motor function</td>
</tr>
<tr>
<td>F840</td>
<td>Autistic disorder</td>
</tr>
<tr>
<td>F88</td>
<td>Other disorders of psychological development</td>
</tr>
<tr>
<td>F900</td>
<td>Attention-deficit hyperactivity disorder, predominantly inattentive type</td>
</tr>
<tr>
<td>F901</td>
<td>Attention-deficit hyperactivity disorder, predominantly hyperactive type</td>
</tr>
<tr>
<td>F902</td>
<td>Attention-deficit hyperactivity disorder, combined type</td>
</tr>
<tr>
<td>F908</td>
<td>Attention-deficit hyperactivity disorder, other type</td>
</tr>
<tr>
<td>H0589</td>
<td>Other disorders of orbit</td>
</tr>
<tr>
<td>H9325</td>
<td>Central auditory processing disorder</td>
</tr>
<tr>
<td>I77810</td>
<td>Thoracic aortic ectasia</td>
</tr>
<tr>
<td>I77811</td>
<td>Abdominal aortic ectasia</td>
</tr>
<tr>
<td>I77812</td>
<td>Thoracoabdominal aortic ectasia</td>
</tr>
<tr>
<td>I77819</td>
<td>Aortic ectasia, unspecified site</td>
</tr>
<tr>
<td>M2600</td>
<td>Unspecified anomaly of jaw size</td>
</tr>
<tr>
<td>M2601</td>
<td>Maxillary hyperplasia</td>
</tr>
<tr>
<td>M2602</td>
<td>Maxillary hypoplasia</td>
</tr>
<tr>
<td>M2603</td>
<td>Mandibular hyperplasia</td>
</tr>
<tr>
<td>M2604</td>
<td>Mandibular hypoplasia</td>
</tr>
<tr>
<td>M2605</td>
<td>Macrogenia</td>
</tr>
<tr>
<td>M2606</td>
<td>Microgenia</td>
</tr>
<tr>
<td>M2607</td>
<td>Excessive tuberosity of jaw</td>
</tr>
<tr>
<td>M2609</td>
<td>Other specified anomalies of jaw size</td>
</tr>
<tr>
<td>N6482</td>
<td>Hypoplasia of breast</td>
</tr>
<tr>
<td>P293</td>
<td>Persistent fetal circulation</td>
</tr>
<tr>
<td>Q000</td>
<td>Anencephaly</td>
</tr>
<tr>
<td>Q001</td>
<td>Craniorachischisis</td>
</tr>
<tr>
<td>Q002</td>
<td>Iniencephaly</td>
</tr>
<tr>
<td>Q010</td>
<td>Frontal encephalocele</td>
</tr>
<tr>
<td>Q011</td>
<td>Nasofrontal encephalocele</td>
</tr>
<tr>
<td>Q012</td>
<td>Occipital encephalocele</td>
</tr>
<tr>
<td>Q018</td>
<td>Encephalocele of other sites</td>
</tr>
<tr>
<td>Q02</td>
<td>Microcephaly</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q030</td>
<td>Malformations of aqueduct of Sylvius</td>
</tr>
<tr>
<td>Q031</td>
<td>Atresia of foramina of Magendie and Luschka</td>
</tr>
<tr>
<td>Q038</td>
<td>Other congenital hydrocephalus</td>
</tr>
<tr>
<td>Q040</td>
<td>Congenital malformations of corpus callosum</td>
</tr>
<tr>
<td>Q041</td>
<td>Arhinencephaly</td>
</tr>
<tr>
<td>Q042</td>
<td>Holoprosencephaly</td>
</tr>
<tr>
<td>Q045</td>
<td>Megalencephaly</td>
</tr>
<tr>
<td>Q046</td>
<td>Congenital cerebral cysts</td>
</tr>
<tr>
<td>Q048</td>
<td>Other specified congenital malformations of brain</td>
</tr>
<tr>
<td>Q050</td>
<td>Cervical spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>Q051</td>
<td>Thoracic spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>Q052</td>
<td>Lumbar spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>Q054</td>
<td>Unspecified spina bifida with hydrocephalus</td>
</tr>
<tr>
<td>Q055</td>
<td>Cervical spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>Q056</td>
<td>Thoracic spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>Q057</td>
<td>Lumbar spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>Q058</td>
<td>Sacral spina bifida without hydrocephalus</td>
</tr>
<tr>
<td>Q062</td>
<td>Diastematomyelia</td>
</tr>
<tr>
<td>Q064</td>
<td>Hydromyelia</td>
</tr>
<tr>
<td>Q068</td>
<td>Other specified congenital malformations of spinal cord</td>
</tr>
<tr>
<td>Q0701</td>
<td>Arnold-Chiari syndrome with spina bifida</td>
</tr>
<tr>
<td>Q0702</td>
<td>Arnold-Chiari syndrome with hydrocephalus</td>
</tr>
<tr>
<td>Q0703</td>
<td>Arnold-Chiari syndrome with spina bifida and hydrocephalus</td>
</tr>
<tr>
<td>Q078</td>
<td>Other specified congenital malformations of nervous system</td>
</tr>
<tr>
<td>Q079</td>
<td>Congenital malformation of nervous system, unspecified</td>
</tr>
<tr>
<td>Q100</td>
<td>Congenital ptosis</td>
</tr>
<tr>
<td>Q101</td>
<td>Congenital ectropion</td>
</tr>
<tr>
<td>Q102</td>
<td>Congenital entropion</td>
</tr>
<tr>
<td>Q103</td>
<td>Other congenital malformations of eyelid</td>
</tr>
<tr>
<td>Q104</td>
<td>Absence and agenesis of lacrimal apparatus</td>
</tr>
<tr>
<td>Q106</td>
<td>Other congenital malformations of lacrimal apparatus</td>
</tr>
<tr>
<td>Q107</td>
<td>Congenital malformation of orbit</td>
</tr>
<tr>
<td>Q110</td>
<td>Cystic eyeball</td>
</tr>
<tr>
<td>Q111</td>
<td>Other anophthalmos</td>
</tr>
<tr>
<td>Q112</td>
<td>Microphthalmos</td>
</tr>
<tr>
<td>Q113</td>
<td>Macrophthalmos</td>
</tr>
<tr>
<td>Q120</td>
<td>Congenital cataract</td>
</tr>
<tr>
<td>Q121</td>
<td>Congenital displaced lens</td>
</tr>
<tr>
<td>Q123</td>
<td>Congenital aphakia</td>
</tr>
<tr>
<td>Q124</td>
<td>Spherophakia</td>
</tr>
<tr>
<td>Q128</td>
<td>Other congenital lens malformations</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>Q129</td>
<td>Congenital lens malformation, unspecified</td>
</tr>
<tr>
<td>Q130</td>
<td>Coloboma of iris</td>
</tr>
<tr>
<td>Q131</td>
<td>Absence of iris</td>
</tr>
<tr>
<td>Q132</td>
<td>Other congenital malformations of iris</td>
</tr>
<tr>
<td>Q133</td>
<td>Congenital corneal opacity</td>
</tr>
<tr>
<td>Q134</td>
<td>Other congenital corneal malformations</td>
</tr>
<tr>
<td>Q135</td>
<td>Blue sclera</td>
</tr>
<tr>
<td>Q1381</td>
<td>Rieger’s anomaly</td>
</tr>
<tr>
<td>Q1389</td>
<td>Other congenital malformations of anterior segment of eye</td>
</tr>
<tr>
<td>Q140</td>
<td>Congenital malformation of vitreous humor</td>
</tr>
<tr>
<td>Q141</td>
<td>Congenital malformation of retina</td>
</tr>
<tr>
<td>Q142</td>
<td>Congenital malformation of optic disc</td>
</tr>
<tr>
<td>Q143</td>
<td>Congenital malformation of choroid</td>
</tr>
<tr>
<td>Q148</td>
<td>Other congenital malformations of posterior segment of eye</td>
</tr>
<tr>
<td>Q150</td>
<td>Congenital glaucoma</td>
</tr>
<tr>
<td>Q158</td>
<td>Other specified congenital malformations of eye</td>
</tr>
<tr>
<td>Q159</td>
<td>Congenital malformation of eye, unspecified</td>
</tr>
<tr>
<td>Q160</td>
<td>Congenital absence of (ear) auricle</td>
</tr>
<tr>
<td>Q161</td>
<td>Congenital absence, atresia and stricture of auditory canal (external)</td>
</tr>
<tr>
<td>Q162</td>
<td>Absence of eustachian tube</td>
</tr>
<tr>
<td>Q163</td>
<td>Congenital malformation of ear ossicles</td>
</tr>
<tr>
<td>Q164</td>
<td>Other congenital malformations of middle ear</td>
</tr>
<tr>
<td>Q165</td>
<td>Congenital malformation of inner ear</td>
</tr>
<tr>
<td>Q169</td>
<td>Congenital malformation of ear causing impairment of hearing, unspecified</td>
</tr>
<tr>
<td>Q170</td>
<td>Accessory auricle</td>
</tr>
<tr>
<td>Q171</td>
<td>Macrotia</td>
</tr>
<tr>
<td>Q172</td>
<td>Microtia</td>
</tr>
<tr>
<td>Q173</td>
<td>Other misshapen ear</td>
</tr>
<tr>
<td>Q174</td>
<td>Misplaced ear</td>
</tr>
<tr>
<td>Q175</td>
<td>Prominent ear</td>
</tr>
<tr>
<td>Q178</td>
<td>Other specified congenital malformations of ear</td>
</tr>
<tr>
<td>Q179</td>
<td>Congenital malformation of ear, unspecified</td>
</tr>
<tr>
<td>Q180</td>
<td>Sinus, fistula and cyst of branchial cleft</td>
</tr>
<tr>
<td>Q181</td>
<td>Preauricular sinus and cyst</td>
</tr>
<tr>
<td>Q182</td>
<td>Other branchial cleft malformations</td>
</tr>
<tr>
<td>Q183</td>
<td>Webbing of neck</td>
</tr>
<tr>
<td>Q184</td>
<td>Macrostomia</td>
</tr>
<tr>
<td>Q185</td>
<td>Microstomia</td>
</tr>
<tr>
<td>Q186</td>
<td>Macrocheilia</td>
</tr>
<tr>
<td>Q187</td>
<td>Microcheilia</td>
</tr>
<tr>
<td>Q188</td>
<td>Other specified congenital malformations of face and neck</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>Q189</td>
<td>Congenital malformation of face and neck, unspecified</td>
</tr>
<tr>
<td>Q200</td>
<td>Common arterial trunk</td>
</tr>
<tr>
<td>Q201</td>
<td>Double outlet right ventricle</td>
</tr>
<tr>
<td>Q202</td>
<td>Double outlet left ventricle</td>
</tr>
<tr>
<td>Q203</td>
<td>Discordant ventriculoarterial connection</td>
</tr>
<tr>
<td>Q204</td>
<td>Double inlet ventricle</td>
</tr>
<tr>
<td>Q205</td>
<td>Discordant atrioventricular connection</td>
</tr>
<tr>
<td>Q206</td>
<td>Isomerism of atrial appendages</td>
</tr>
<tr>
<td>Q208</td>
<td>Other congenital malformations of cardiac chambers and connections</td>
</tr>
<tr>
<td>Q209</td>
<td>Congenital malformation of cardiac chambers and connections, unspecified</td>
</tr>
<tr>
<td>Q210</td>
<td>Ventricular septal defect</td>
</tr>
<tr>
<td>Q211</td>
<td>Atrial septal defect</td>
</tr>
<tr>
<td>Q212</td>
<td>Atrioventricular septal defect</td>
</tr>
<tr>
<td>Q213</td>
<td>Tetralogy of Fallot</td>
</tr>
<tr>
<td>Q214</td>
<td>Aortopulmonary septal defect</td>
</tr>
<tr>
<td>Q218</td>
<td>Other congenital malformations of cardiac septa</td>
</tr>
<tr>
<td>Q219</td>
<td>Congenital malformation of cardiac septum, unspecified</td>
</tr>
<tr>
<td>Q220</td>
<td>Pulmonary valve atresia</td>
</tr>
<tr>
<td>Q221</td>
<td>Congenital pulmonary valve stenosis</td>
</tr>
<tr>
<td>Q222</td>
<td>Congenital pulmonary valve insufficiency</td>
</tr>
<tr>
<td>Q223</td>
<td>Other congenital malformations of pulmonary valve</td>
</tr>
<tr>
<td>Q224</td>
<td>Congenital tricuspid stenosis</td>
</tr>
<tr>
<td>Q225</td>
<td>Ebstein's anomaly</td>
</tr>
<tr>
<td>Q228</td>
<td>Other congenital malformations of tricuspid valve</td>
</tr>
<tr>
<td>Q230</td>
<td>Congenital stenosis of aortic valve</td>
</tr>
<tr>
<td>Q231</td>
<td>Congenital insufficiency of aortic valve</td>
</tr>
<tr>
<td>Q232</td>
<td>Congenital mitral stenosis</td>
</tr>
<tr>
<td>Q233</td>
<td>Congenital mitral insufficiency</td>
</tr>
<tr>
<td>Q234</td>
<td>Hypoplastic left heart syndrome</td>
</tr>
<tr>
<td>Q238</td>
<td>Other congenital malformations of aortic and mitral valves</td>
</tr>
<tr>
<td>Q240</td>
<td>Dextrocardia</td>
</tr>
<tr>
<td>Q241</td>
<td>Levocardia</td>
</tr>
<tr>
<td>Q242</td>
<td>Cor triatriatum</td>
</tr>
<tr>
<td>Q243</td>
<td>Pulmonary infundibular stenosis</td>
</tr>
<tr>
<td>Q244</td>
<td>Congenital subaortic stenosis</td>
</tr>
<tr>
<td>Q245</td>
<td>Malformation of coronary vessels</td>
</tr>
<tr>
<td>Q246</td>
<td>Congenital heart block</td>
</tr>
<tr>
<td>Q248</td>
<td>Other specified congenital malformations of heart</td>
</tr>
<tr>
<td>Q249</td>
<td>Congenital malformation of heart, unspecified</td>
</tr>
<tr>
<td>Q250</td>
<td>Patent ductus arteriosus</td>
</tr>
<tr>
<td>Q251</td>
<td>Coarctation of aorta</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Q2521</td>
<td>Interruption of aortic arch</td>
</tr>
<tr>
<td>Q2529</td>
<td>Other atresia of aorta</td>
</tr>
<tr>
<td>Q2530</td>
<td>Supravalvular aortic stenosis</td>
</tr>
<tr>
<td>Q2540</td>
<td>Congenital malformation of aorta unspecified</td>
</tr>
<tr>
<td>Q2541</td>
<td>Absence and aplasia of aorta</td>
</tr>
<tr>
<td>Q2542</td>
<td>Hypoplasia of aorta</td>
</tr>
<tr>
<td>Q2543</td>
<td>Congenital aneurysm of aorta</td>
</tr>
<tr>
<td>Q2544</td>
<td>Congenital dilation of aorta</td>
</tr>
<tr>
<td>Q2545</td>
<td>Double aortic arch</td>
</tr>
<tr>
<td>Q2546</td>
<td>Tortuous aortic arch</td>
</tr>
<tr>
<td>Q2547</td>
<td>Right aortic arch</td>
</tr>
<tr>
<td>Q2548</td>
<td>Anomalous origin of subclavian artery</td>
</tr>
<tr>
<td>Q2549</td>
<td>Other congenital malformations of aorta</td>
</tr>
<tr>
<td>Q2572</td>
<td>Congenital pulmonary arteriovenous malformation</td>
</tr>
<tr>
<td>Q2573</td>
<td>Congenital malformation of great arteries, unspecified</td>
</tr>
<tr>
<td>Q2590</td>
<td>Congenital stenosis of vena cava</td>
</tr>
<tr>
<td>Q2600</td>
<td>Persistent left superior vena cava</td>
</tr>
<tr>
<td>Q2610</td>
<td>Total anomalous pulmonary venous connection</td>
</tr>
<tr>
<td>Q2620</td>
<td>Partial anomalous pulmonary venous connection</td>
</tr>
<tr>
<td>Q2630</td>
<td>Anomalous portal venous connection</td>
</tr>
<tr>
<td>Q2660</td>
<td>Portal vein-hepatic artery fistula</td>
</tr>
<tr>
<td>Q2670</td>
<td>Other congenital malformations of great veins</td>
</tr>
<tr>
<td>Q2680</td>
<td>Congenital malformation of great vein, unspecified</td>
</tr>
<tr>
<td>Q2690</td>
<td>Congenital absence and hypoplasia of umbilical artery</td>
</tr>
<tr>
<td>Q2700</td>
<td>Congenital renal artery stenosis</td>
</tr>
<tr>
<td>Q2710</td>
<td>Other congenital malformations of renal artery</td>
</tr>
<tr>
<td>Q2720</td>
<td>Arteriovenous malformation, site unspecified</td>
</tr>
<tr>
<td>Q2730</td>
<td>Arteriovenous malformation of vessel of upper limb</td>
</tr>
<tr>
<td>Q2740</td>
<td>Arteriovenous malformation of vessel of lower limb</td>
</tr>
<tr>
<td>Q2750</td>
<td>Arteriovenous malformation of digestive system vessel</td>
</tr>
<tr>
<td>Q2760</td>
<td>Arteriovenous malformation of renal vessel</td>
</tr>
<tr>
<td>Q2770</td>
<td>Congenital phlebectasia</td>
</tr>
<tr>
<td>Q2780</td>
<td>Other specified congenital malformations of peripheral vascular system</td>
</tr>
<tr>
<td>Q2790</td>
<td>Congenital malformation of peripheral vascular system, unspecified</td>
</tr>
<tr>
<td>Q2800</td>
<td>Arteriovenous malformation of precerebral vessels</td>
</tr>
<tr>
<td>Q2810</td>
<td>Other malformations of precerebral vessels</td>
</tr>
<tr>
<td>Q2820</td>
<td>Arteriovenous malformation of cerebral vessels</td>
</tr>
<tr>
<td>Q2830</td>
<td>Other malformations of cerebral vessels</td>
</tr>
<tr>
<td>Q2840</td>
<td>Other specified congenital malformations of circulatory system</td>
</tr>
<tr>
<td>Q2850</td>
<td>Congenital malformation of circulatory system, unspecified</td>
</tr>
<tr>
<td>Q2860</td>
<td>Choanal atresia</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q301</td>
<td>Agenesis and underdevelopment of nose</td>
</tr>
<tr>
<td>Q302</td>
<td>Fissured, notched and cleft nose</td>
</tr>
<tr>
<td>Q303</td>
<td>Congenital perforated nasal septum</td>
</tr>
<tr>
<td>Q308</td>
<td>Other congenital malformations of nose</td>
</tr>
<tr>
<td>Q309</td>
<td>Congenital malformation of nose, unspecified</td>
</tr>
<tr>
<td>Q310</td>
<td>Web of larynx</td>
</tr>
<tr>
<td>Q311</td>
<td>Congenital subglottic stenosis</td>
</tr>
<tr>
<td>Q312</td>
<td>Laryngeal hypoplasia</td>
</tr>
<tr>
<td>Q313</td>
<td>Laryngocele</td>
</tr>
<tr>
<td>Q315</td>
<td>Congenital laryngomalacia</td>
</tr>
<tr>
<td>Q318</td>
<td>Other congenital malformations of larynx</td>
</tr>
<tr>
<td>Q320</td>
<td>Congenital tracheomalacia</td>
</tr>
<tr>
<td>Q321</td>
<td>Other congenital malformations of trachea</td>
</tr>
<tr>
<td>Q322</td>
<td>Congenital bronchomalacia</td>
</tr>
<tr>
<td>Q323</td>
<td>Congenital stenosis of bronchus</td>
</tr>
<tr>
<td>Q324</td>
<td>Other congenital malformations of bronchus</td>
</tr>
<tr>
<td>Q330</td>
<td>Congenital cystic lung</td>
</tr>
<tr>
<td>Q331</td>
<td>Accessory lobe of lung</td>
</tr>
<tr>
<td>Q332</td>
<td>Sequestration of lung</td>
</tr>
<tr>
<td>Q333</td>
<td>Agenesis of lung</td>
</tr>
<tr>
<td>Q334</td>
<td>Congenital bronchiectasis</td>
</tr>
<tr>
<td>Q335</td>
<td>Ectopic tissue in lung</td>
</tr>
<tr>
<td>Q336</td>
<td>Congenital hypoplasia and dysplasia of lung</td>
</tr>
<tr>
<td>Q338</td>
<td>Other congenital malformations of lung</td>
</tr>
<tr>
<td>Q339</td>
<td>Congenital malformation of lung, unspecified</td>
</tr>
<tr>
<td>Q348</td>
<td>Other specified congenital malformations of respiratory system</td>
</tr>
<tr>
<td>Q349</td>
<td>Congenital malformation of respiratory system, unspecified</td>
</tr>
<tr>
<td>Q351</td>
<td>Cleft hard palate</td>
</tr>
<tr>
<td>Q353</td>
<td>Cleft soft palate</td>
</tr>
<tr>
<td>Q359</td>
<td>Cleft palate, unspecified</td>
</tr>
<tr>
<td>Q360</td>
<td>Cleft lip, bilateral</td>
</tr>
<tr>
<td>Q369</td>
<td>Cleft lip, unilateral</td>
</tr>
<tr>
<td>Q370</td>
<td>Cleft hard palate with bilateral cleft lip</td>
</tr>
<tr>
<td>Q371</td>
<td>Cleft hard palate with unilateral cleft lip</td>
</tr>
<tr>
<td>Q372</td>
<td>Cleft soft palate with bilateral cleft lip</td>
</tr>
<tr>
<td>Q373</td>
<td>Cleft soft palate with unilateral cleft lip</td>
</tr>
<tr>
<td>Q374</td>
<td>Cleft hard and soft palate with bilateral cleft lip</td>
</tr>
<tr>
<td>Q375</td>
<td>Cleft hard and soft palate with unilateral cleft lip</td>
</tr>
<tr>
<td>Q380</td>
<td>Congenital malformations of lips, not elsewhere classified</td>
</tr>
<tr>
<td>Q381</td>
<td>Ankyloglossia</td>
</tr>
<tr>
<td>Q382</td>
<td>Macroglossia</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Q383</td>
<td>Other congenital malformations of tongue</td>
</tr>
<tr>
<td>Q384</td>
<td>Congenital malformations of salivary glands and ducts</td>
</tr>
<tr>
<td>Q385</td>
<td>Congenital malformations of palate, not elsewhere classified</td>
</tr>
<tr>
<td>Q386</td>
<td>Other congenital malformations of mouth</td>
</tr>
<tr>
<td>Q387</td>
<td>Congenital pharyngeal pouch</td>
</tr>
<tr>
<td>Q388</td>
<td>Other congenital malformations of pharynx</td>
</tr>
<tr>
<td>Q391</td>
<td>Atresia of esophagus with tracheo-esophageal fistula</td>
</tr>
<tr>
<td>Q392</td>
<td>Congenital tracheo-esophageal fistula without atresia</td>
</tr>
<tr>
<td>Q393</td>
<td>Congenital stenosis and stricture of esophagus</td>
</tr>
<tr>
<td>Q394</td>
<td>Esophageal web</td>
</tr>
<tr>
<td>Q395</td>
<td>Congenital dilatation of esophagus</td>
</tr>
<tr>
<td>Q396</td>
<td>Congenital diverticulum of esophagus</td>
</tr>
<tr>
<td>Q398</td>
<td>Other congenital malformations of esophagus</td>
</tr>
<tr>
<td>Q400</td>
<td>Congenital hypertrophic pyloric stenosis</td>
</tr>
<tr>
<td>Q401</td>
<td>Congenital hiatus hernia</td>
</tr>
<tr>
<td>Q402</td>
<td>Other specified congenital malformations of stomach</td>
</tr>
<tr>
<td>Q408</td>
<td>Other specified congenital malformations of upper alimentary tract</td>
</tr>
<tr>
<td>Q409</td>
<td>Congenital malformation of upper alimentary tract, unspecified</td>
</tr>
<tr>
<td>Q410</td>
<td>Congenital absence, atresia and stenosis of duodenum</td>
</tr>
<tr>
<td>Q411</td>
<td>Congenital absence, atresia and stenosis of jejunum</td>
</tr>
<tr>
<td>Q412</td>
<td>Congenital absence, atresia and stenosis of ileum</td>
</tr>
<tr>
<td>Q419</td>
<td>Congenital absence, atresia and stenosis of small intestine, part unspecified</td>
</tr>
<tr>
<td>Q420</td>
<td>Congenital absence, atresia and stenosis of rectum with fistula</td>
</tr>
<tr>
<td>Q421</td>
<td>Congenital absence, atresia and stenosis of rectum without fistula</td>
</tr>
<tr>
<td>Q422</td>
<td>Congenital absence, atresia and stenosis of anus with fistula</td>
</tr>
<tr>
<td>Q423</td>
<td>Congenital absence, atresia and stenosis of anus without fistula</td>
</tr>
<tr>
<td>Q428</td>
<td>Congenital absence, atresia and stenosis of other parts of large intestine</td>
</tr>
<tr>
<td>Q430</td>
<td>Meckel's diverticulum (displaced) (hypertrophic)</td>
</tr>
<tr>
<td>Q431</td>
<td>Hirschsprung's disease</td>
</tr>
<tr>
<td>Q432</td>
<td>Other congenital functional disorders of colon</td>
</tr>
<tr>
<td>Q433</td>
<td>Congenital malformations of intestinal fixation</td>
</tr>
<tr>
<td>Q434</td>
<td>Duplication of intestine</td>
</tr>
<tr>
<td>Q435</td>
<td>Ectopic anus</td>
</tr>
<tr>
<td>Q437</td>
<td>Persistent cloaca</td>
</tr>
<tr>
<td>Q438</td>
<td>Other specified congenital malformations of intestine</td>
</tr>
<tr>
<td>Q440</td>
<td>Agenesis, aplasia and hypoplasia of gallbladder</td>
</tr>
<tr>
<td>Q441</td>
<td>Other congenital malformations of gallbladder</td>
</tr>
<tr>
<td>Q442</td>
<td>Atresia of bile ducts</td>
</tr>
<tr>
<td>Q443</td>
<td>Congenital stenosis and stricture of bile ducts</td>
</tr>
<tr>
<td>Q444</td>
<td>Choledochal cyst</td>
</tr>
<tr>
<td>Q445</td>
<td>Other congenital malformations of bile ducts</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q446</td>
<td>Cystic disease of liver</td>
</tr>
<tr>
<td>Q447</td>
<td>Other congenital malformations of liver</td>
</tr>
<tr>
<td>Q450</td>
<td>Agenesis, aplasia and hypoplasia of pancreas</td>
</tr>
<tr>
<td>Q451</td>
<td>Annular pancreas</td>
</tr>
<tr>
<td>Q452</td>
<td>Congenital pancreatic cyst</td>
</tr>
<tr>
<td>Q453</td>
<td>Other congenital malformations of pancreas and pancreatic duct</td>
</tr>
<tr>
<td>Q458</td>
<td>Other specified congenital malformations of digestive system</td>
</tr>
<tr>
<td>Q459</td>
<td>Congenital malformation of digestive system, unspecified</td>
</tr>
<tr>
<td>Q5001</td>
<td>Congenital absence of ovary, unilateral</td>
</tr>
<tr>
<td>Q5002</td>
<td>Congenital absence of ovary, bilateral</td>
</tr>
<tr>
<td>Q501</td>
<td>Developmental ovarian cyst</td>
</tr>
<tr>
<td>Q502</td>
<td>Congenital torsion of ovary</td>
</tr>
<tr>
<td>Q5031</td>
<td>Accessory ovary</td>
</tr>
<tr>
<td>Q5032</td>
<td>Ovarian streak</td>
</tr>
<tr>
<td>Q5039</td>
<td>Other congenital malformation of ovary</td>
</tr>
<tr>
<td>Q504</td>
<td>Embryonic cyst of fallopian tube</td>
</tr>
<tr>
<td>Q505</td>
<td>Embryonic cyst of broad ligament</td>
</tr>
<tr>
<td>Q506</td>
<td>Other congenital malformations of fallopian tube and broad ligament</td>
</tr>
<tr>
<td>Q510</td>
<td>Agenesis and aplasia of uterus</td>
</tr>
<tr>
<td>Q5110</td>
<td>Doubling of uterus with doubling of cervix and vagina without obstruction</td>
</tr>
<tr>
<td>Q5111</td>
<td>Doubling of uterus with doubling of cervix and vagina with obstruction</td>
</tr>
<tr>
<td>Q512</td>
<td>Other doubling of uterus</td>
</tr>
<tr>
<td>Q515</td>
<td>Agenesis and aplasia of cervix</td>
</tr>
<tr>
<td>Q516</td>
<td>Embryonic cyst of cervix</td>
</tr>
<tr>
<td>Q517</td>
<td>Congenital fistulae between uterus and digestive and urinary tracts</td>
</tr>
<tr>
<td>Q51811</td>
<td>Hypoplasia of uterus</td>
</tr>
<tr>
<td>Q51821</td>
<td>Hypoplasia of cervix</td>
</tr>
<tr>
<td>Q51828</td>
<td>Other congenital malformations of cervix</td>
</tr>
<tr>
<td>Q520</td>
<td>Congenital absence of vagina</td>
</tr>
<tr>
<td>Q5210</td>
<td>Doubling of vagina, unspecified</td>
</tr>
<tr>
<td>Q522</td>
<td>Congenital rectovaginal fistula</td>
</tr>
<tr>
<td>Q523</td>
<td>Imperforate hymen</td>
</tr>
<tr>
<td>Q524</td>
<td>Other congenital malformations of vagina</td>
</tr>
<tr>
<td>Q525</td>
<td>Fusion of labia</td>
</tr>
<tr>
<td>Q526</td>
<td>Congenital malformation of clitoris</td>
</tr>
<tr>
<td>Q5270</td>
<td>Unspecified congenital malformations of vulva</td>
</tr>
<tr>
<td>Q5271</td>
<td>Congenital absence of vulva</td>
</tr>
<tr>
<td>Q5279</td>
<td>Other congenital malformations of vulva</td>
</tr>
<tr>
<td>Q528</td>
<td>Other specified congenital malformations of female genitalia</td>
</tr>
<tr>
<td>Q529</td>
<td>Congenital malformation of female genitalia, unspecified</td>
</tr>
<tr>
<td>Q5300</td>
<td>Ectopic testis, unspecified</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Q5301</td>
<td>Ectopic testis, unilateral</td>
</tr>
<tr>
<td>Q5302</td>
<td>Ectopic testes, bilateral</td>
</tr>
<tr>
<td>Q5310</td>
<td>Unspecified undescended testicle, unilateral</td>
</tr>
<tr>
<td>Q5311</td>
<td>Abdominal testis, unilateral</td>
</tr>
<tr>
<td>Q5312</td>
<td>Ectopic perineal testis, unilateral</td>
</tr>
<tr>
<td>Q5320</td>
<td>Undescended testicle, unspecified, bilateral</td>
</tr>
<tr>
<td>Q5321</td>
<td>Abdominal testis, bilateral</td>
</tr>
<tr>
<td>Q5322</td>
<td>Ectopic perineal testis, bilateral</td>
</tr>
<tr>
<td>Q539</td>
<td>Undescended testicle, unspecified</td>
</tr>
<tr>
<td>Q540</td>
<td>Hypospadias, balanic</td>
</tr>
<tr>
<td>Q541</td>
<td>Hypospadias, penile</td>
</tr>
<tr>
<td>Q542</td>
<td>Hypospadias, penoscrotal</td>
</tr>
<tr>
<td>Q543</td>
<td>Hypospadias, perineal</td>
</tr>
<tr>
<td>Q544</td>
<td>Congenital chordee</td>
</tr>
<tr>
<td>Q548</td>
<td>Other hypospadias</td>
</tr>
<tr>
<td>Q550</td>
<td>Absence and aplasia of testis</td>
</tr>
<tr>
<td>Q551</td>
<td>Hypoplasia of testis and scrotum</td>
</tr>
<tr>
<td>Q5521</td>
<td>Polyorchism</td>
</tr>
<tr>
<td>Q5522</td>
<td>Retractile testis</td>
</tr>
<tr>
<td>Q5523</td>
<td>Scrotal transposition</td>
</tr>
<tr>
<td>Q5529</td>
<td>Other congenital malformations of testis and scrotum</td>
</tr>
<tr>
<td>Q553</td>
<td>Atresia of vas deferens</td>
</tr>
<tr>
<td>Q554</td>
<td>Other congenital malformations of vas deferens, epididymis, seminal vesicles and prostate</td>
</tr>
<tr>
<td>Q555</td>
<td>Congenital absence and aplasia of penis</td>
</tr>
<tr>
<td>Q5561</td>
<td>Curvature of penis (lateral)</td>
</tr>
<tr>
<td>Q5562</td>
<td>Hypoplasia of penis</td>
</tr>
<tr>
<td>Q5563</td>
<td>Congenital torsion of penis</td>
</tr>
<tr>
<td>Q5564</td>
<td>Hidden penis</td>
</tr>
<tr>
<td>Q5569</td>
<td>Other congenital malformation of penis</td>
</tr>
<tr>
<td>Q558</td>
<td>Other specified congenital malformations of male genital organs</td>
</tr>
<tr>
<td>Q559</td>
<td>Congenital malformation of male genital organ, unspecified</td>
</tr>
<tr>
<td>Q560</td>
<td>Hermaphroditism, not elsewhere classified</td>
</tr>
<tr>
<td>Q561</td>
<td>Male pseudohermaphroditism, not elsewhere classified</td>
</tr>
<tr>
<td>Q562</td>
<td>Female pseudohermaphroditism, not elsewhere classified</td>
</tr>
<tr>
<td>Q563</td>
<td>Pseudohermaphroditism, unspecified</td>
</tr>
<tr>
<td>Q564</td>
<td>Indeterminate sex, unspecified</td>
</tr>
<tr>
<td>Q600</td>
<td>Renal agenesis, unilateral</td>
</tr>
<tr>
<td>Q601</td>
<td>Renal agenesis, bilateral</td>
</tr>
<tr>
<td>Q603</td>
<td>Renal hypoplasia, unilateral</td>
</tr>
<tr>
<td>Q604</td>
<td>Renal hypoplasia, bilateral</td>
</tr>
<tr>
<td>Q606</td>
<td>Potter's syndrome</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q6101</td>
<td>Congenital single renal cyst</td>
</tr>
<tr>
<td>Q6119</td>
<td>Other polycystic kidney, infantile type</td>
</tr>
<tr>
<td>Q612</td>
<td>Polycystic kidney, adult type</td>
</tr>
<tr>
<td>Q613</td>
<td>Polycystic kidney, unspecified</td>
</tr>
<tr>
<td>Q614</td>
<td>Renal dysplasia</td>
</tr>
<tr>
<td>Q615</td>
<td>Medullary cystic kidney</td>
</tr>
<tr>
<td>Q618</td>
<td>Other cystic kidney diseases</td>
</tr>
<tr>
<td>Q619</td>
<td>Cystic kidney disease, unspecified</td>
</tr>
<tr>
<td>Q6211</td>
<td>Congenital occlusion of ureteropelvic junction</td>
</tr>
<tr>
<td>Q6212</td>
<td>Congenital occlusion of ureterovesical orifice</td>
</tr>
<tr>
<td>Q622</td>
<td>Congenital megaureter</td>
</tr>
<tr>
<td>Q6231</td>
<td>Congenital ureterocele, orthotopic</td>
</tr>
<tr>
<td>Q6239</td>
<td>Other obstructive defects of renal pelvis and ureter</td>
</tr>
<tr>
<td>Q624</td>
<td>Agenesis of ureter</td>
</tr>
<tr>
<td>Q625</td>
<td>Duplication of ureter</td>
</tr>
<tr>
<td>Q6261</td>
<td>Deviation of ureter</td>
</tr>
<tr>
<td>Q6262</td>
<td>Displacement of ureter</td>
</tr>
<tr>
<td>Q6263</td>
<td>Anomalous implantation of ureter</td>
</tr>
<tr>
<td>Q628</td>
<td>Other congenital malformations of ureter</td>
</tr>
<tr>
<td>Q630</td>
<td>Accessory kidney</td>
</tr>
<tr>
<td>Q631</td>
<td>Lobulated, fused and horseshoe kidney</td>
</tr>
<tr>
<td>Q632</td>
<td>Ectopic kidney</td>
</tr>
<tr>
<td>Q633</td>
<td>Hyperplastic and giant kidney</td>
</tr>
<tr>
<td>Q638</td>
<td>Other specified congenital malformations of kidney</td>
</tr>
<tr>
<td>Q640</td>
<td>Epispadias</td>
</tr>
<tr>
<td>Q6410</td>
<td>Exstrophy of urinary bladder, unspecified</td>
</tr>
<tr>
<td>Q6411</td>
<td>Supravesical fissure of urinary bladder</td>
</tr>
<tr>
<td>Q6412</td>
<td>Cloacal extrophy of urinary bladder</td>
</tr>
<tr>
<td>Q6419</td>
<td>Other extrophy of urinary bladder</td>
</tr>
<tr>
<td>Q642</td>
<td>Congenital posterior urethral valves</td>
</tr>
<tr>
<td>Q6431</td>
<td>Congenital bladder neck obstruction</td>
</tr>
<tr>
<td>Q6432</td>
<td>Congenital stricture of urethra</td>
</tr>
<tr>
<td>Q6433</td>
<td>Congenital stricture of urinary meatus</td>
</tr>
<tr>
<td>Q6439</td>
<td>Other atresia and stenosis of urethra and bladder neck</td>
</tr>
<tr>
<td>Q644</td>
<td>Malformation of urachus</td>
</tr>
<tr>
<td>Q645</td>
<td>Congenital absence of bladder and urethra</td>
</tr>
<tr>
<td>Q646</td>
<td>Congenital diverticulum of bladder</td>
</tr>
<tr>
<td>Q6471</td>
<td>Congenital prolapse of urethra</td>
</tr>
<tr>
<td>Q6472</td>
<td>Congenital prolapse of urinary meatus</td>
</tr>
<tr>
<td>Q6473</td>
<td>Congenital urethrorectal fistula</td>
</tr>
<tr>
<td>Q6474</td>
<td>Double urethra</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Q6475</td>
<td>Double urinary meatus</td>
</tr>
<tr>
<td>Q649</td>
<td>Congenital malformation of urinary system, unspecified</td>
</tr>
<tr>
<td>Q6501</td>
<td>Congenital dislocation of right hip, unilateral</td>
</tr>
<tr>
<td>Q6502</td>
<td>Congenital dislocation of left hip, unilateral</td>
</tr>
<tr>
<td>Q651</td>
<td>Congenital dislocation of hip, bilateral</td>
</tr>
<tr>
<td>Q6531</td>
<td>Congenital partial dislocation of right hip, unilateral</td>
</tr>
<tr>
<td>Q6532</td>
<td>Congenital partial dislocation of left hip, unilateral</td>
</tr>
<tr>
<td>Q654</td>
<td>Congenital partial dislocation of hip, bilateral</td>
</tr>
<tr>
<td>Q6581</td>
<td>Congenital coxa valga</td>
</tr>
<tr>
<td>Q6582</td>
<td>Congenital coxa vara</td>
</tr>
<tr>
<td>Q6589</td>
<td>Other specified congenital deformities of hip</td>
</tr>
<tr>
<td>Q660</td>
<td>Congenital talipes equinovarus</td>
</tr>
<tr>
<td>Q6621</td>
<td>Congenital metatarsus primus varus</td>
</tr>
<tr>
<td>Q6622</td>
<td>Congenital metatarsus adductus</td>
</tr>
<tr>
<td>Q663</td>
<td>Other congenital varus deformities of feet</td>
</tr>
<tr>
<td>Q664</td>
<td>Congenital talipes calcaneovalgus</td>
</tr>
<tr>
<td>Q6651</td>
<td>Congenital pes planus, right foot</td>
</tr>
<tr>
<td>Q6652</td>
<td>Congenital pes planus, left foot</td>
</tr>
<tr>
<td>Q666</td>
<td>Other congenital valgus deformities of feet</td>
</tr>
<tr>
<td>Q667</td>
<td>Congenital pes cavus</td>
</tr>
<tr>
<td>Q6681</td>
<td>Congenital vertical talus deformity, right foot</td>
</tr>
<tr>
<td>Q6682</td>
<td>Congenital vertical talus deformity, left foot</td>
</tr>
<tr>
<td>Q6689</td>
<td>Other specified congenital deformities of feet</td>
</tr>
<tr>
<td>Q670</td>
<td>Congenital facial asymmetry</td>
</tr>
<tr>
<td>Q671</td>
<td>Congenital compression facies</td>
</tr>
<tr>
<td>Q672</td>
<td>Dolichocephaly</td>
</tr>
<tr>
<td>Q673</td>
<td>Plagiocephaly</td>
</tr>
<tr>
<td>Q674</td>
<td>Other congenital deformities of skull, face and jaw</td>
</tr>
<tr>
<td>Q675</td>
<td>Congenital deformity of spine</td>
</tr>
<tr>
<td>Q676</td>
<td>Pectus excavatum</td>
</tr>
<tr>
<td>Q677</td>
<td>Pectus carinatum</td>
</tr>
<tr>
<td>Q678</td>
<td>Other congenital deformities of chest</td>
</tr>
<tr>
<td>Q680</td>
<td>Congenital deformity of sternocleidomastoid muscle</td>
</tr>
<tr>
<td>Q681</td>
<td>Congenital deformity of finger(s) and hand</td>
</tr>
<tr>
<td>Q682</td>
<td>Congenital deformity of knee</td>
</tr>
<tr>
<td>Q683</td>
<td>Congenital bowing of femur</td>
</tr>
<tr>
<td>Q684</td>
<td>Congenital bowing of tibia and fibula</td>
</tr>
<tr>
<td>Q688</td>
<td>Other specified congenital musculoskeletal deformities</td>
</tr>
<tr>
<td>Q690</td>
<td>Accessory finger(s)</td>
</tr>
<tr>
<td>Q691</td>
<td>Accessory thumb(s)</td>
</tr>
<tr>
<td>Q692</td>
<td>Accessory toe(s)</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q699</td>
<td>Polydactyly, unspecified</td>
</tr>
<tr>
<td>Q7001</td>
<td>Fused fingers, right hand</td>
</tr>
<tr>
<td>Q7002</td>
<td>Fused fingers, left hand</td>
</tr>
<tr>
<td>Q7003</td>
<td>Fused fingers, bilateral</td>
</tr>
<tr>
<td>Q7011</td>
<td>Webbed fingers, right hand</td>
</tr>
<tr>
<td>Q7012</td>
<td>Webbed fingers, left hand</td>
</tr>
<tr>
<td>Q7013</td>
<td>Webbed fingers, bilateral</td>
</tr>
<tr>
<td>Q7021</td>
<td>Fused toes, right foot</td>
</tr>
<tr>
<td>Q7022</td>
<td>Fused toes, left foot</td>
</tr>
<tr>
<td>Q7023</td>
<td>Fused toes, bilateral</td>
</tr>
<tr>
<td>Q7031</td>
<td>Webbed toes, right foot</td>
</tr>
<tr>
<td>Q7032</td>
<td>Webbed toes, left foot</td>
</tr>
<tr>
<td>Q7033</td>
<td>Webbed toes, bilateral</td>
</tr>
<tr>
<td>Q709</td>
<td>Syndactyly, unspecified</td>
</tr>
<tr>
<td>Q7101</td>
<td>Congenital complete absence of right upper limb</td>
</tr>
<tr>
<td>Q7102</td>
<td>Congenital complete absence of left upper limb</td>
</tr>
<tr>
<td>Q7103</td>
<td>Congenital complete absence of upper limb, bilateral</td>
</tr>
<tr>
<td>Q7111</td>
<td>Congenital absence of right upper arm and forearm with hand present</td>
</tr>
<tr>
<td>Q7112</td>
<td>Congenital absence of left upper arm and forearm with hand present</td>
</tr>
<tr>
<td>Q7113</td>
<td>Congenital absence of upper arm and forearm with hand present, bilateral</td>
</tr>
<tr>
<td>Q7131</td>
<td>Congenital absence of right hand and finger</td>
</tr>
<tr>
<td>Q7132</td>
<td>Congenital absence of left hand and finger</td>
</tr>
<tr>
<td>Q7133</td>
<td>Congenital absence of hand and finger, bilateral</td>
</tr>
<tr>
<td>Q7141</td>
<td>Longitudinal reduction defect of right radius</td>
</tr>
<tr>
<td>Q7142</td>
<td>Longitudinal reduction defect of left radius</td>
</tr>
<tr>
<td>Q7143</td>
<td>Longitudinal reduction defect of radius, bilateral</td>
</tr>
<tr>
<td>Q7151</td>
<td>Longitudinal reduction defect of right ulna</td>
</tr>
<tr>
<td>Q7152</td>
<td>Longitudinal reduction defect of left ulna</td>
</tr>
<tr>
<td>Q7153</td>
<td>Longitudinal reduction defect of ulna, bilateral</td>
</tr>
<tr>
<td>Q7161</td>
<td>Lobster-claw right hand</td>
</tr>
<tr>
<td>Q7162</td>
<td>Lobster-claw left hand</td>
</tr>
<tr>
<td>Q7163</td>
<td>Lobster-claw hand, bilateral</td>
</tr>
<tr>
<td>Q71811</td>
<td>Congenital shortening of right upper limb</td>
</tr>
<tr>
<td>Q71812</td>
<td>Congenital shortening of left upper limb</td>
</tr>
<tr>
<td>Q71813</td>
<td>Congenital shortening of upper limb, bilateral</td>
</tr>
<tr>
<td>Q71891</td>
<td>Other reduction defects of right upper limb</td>
</tr>
<tr>
<td>Q71892</td>
<td>Other reduction defects of left upper limb</td>
</tr>
<tr>
<td>Q71893</td>
<td>Other reduction defects of upper limb, bilateral</td>
</tr>
<tr>
<td>Q7191</td>
<td>Unspecified reduction defect of right upper limb</td>
</tr>
<tr>
<td>Q7192</td>
<td>Unspecified reduction defect of left upper limb</td>
</tr>
<tr>
<td>Q7193</td>
<td>Unspecified reduction defect of upper limb, bilateral</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Q7201</td>
<td>Congenital complete absence of right lower limb</td>
</tr>
<tr>
<td>Q7202</td>
<td>Congenital complete absence of left lower limb</td>
</tr>
<tr>
<td>Q7203</td>
<td>Congenital complete absence of lower limb, bilateral</td>
</tr>
<tr>
<td>Q7211</td>
<td>Congenital absence of right thigh and lower leg with foot present</td>
</tr>
<tr>
<td>Q7212</td>
<td>Congenital absence of left thigh and lower leg with foot present</td>
</tr>
<tr>
<td>Q7213</td>
<td>Congenital absence of thigh and lower leg with foot present, bilateral</td>
</tr>
<tr>
<td>Q7231</td>
<td>Congenital absence of right foot and toe(s)</td>
</tr>
<tr>
<td>Q7232</td>
<td>Congenital absence of left foot and toe(s)</td>
</tr>
<tr>
<td>Q7233</td>
<td>Congenital absence of foot and toe(s), bilateral</td>
</tr>
<tr>
<td>Q7241</td>
<td>Longitudinal reduction defect of right femur</td>
</tr>
<tr>
<td>Q7242</td>
<td>Longitudinal reduction defect of left femur</td>
</tr>
<tr>
<td>Q7243</td>
<td>Longitudinal reduction defect of femur, bilateral</td>
</tr>
<tr>
<td>Q7251</td>
<td>Longitudinal reduction defect of right tibia</td>
</tr>
<tr>
<td>Q7252</td>
<td>Longitudinal reduction defect of left tibia</td>
</tr>
<tr>
<td>Q7253</td>
<td>Longitudinal reduction defect of tibia, bilateral</td>
</tr>
<tr>
<td>Q7261</td>
<td>Longitudinal reduction defect of right fibula</td>
</tr>
<tr>
<td>Q7262</td>
<td>Longitudinal reduction defect of left fibula</td>
</tr>
<tr>
<td>Q7263</td>
<td>Longitudinal reduction defect of fibula, bilateral</td>
</tr>
<tr>
<td>Q7271</td>
<td>Split foot, right lower limb</td>
</tr>
<tr>
<td>Q7272</td>
<td>Split foot, left lower limb</td>
</tr>
<tr>
<td>Q7273</td>
<td>Split foot, bilateral</td>
</tr>
<tr>
<td>Q72811</td>
<td>Congenital shortening of right lower limb</td>
</tr>
<tr>
<td>Q72812</td>
<td>Congenital shortening of left lower limb</td>
</tr>
<tr>
<td>Q72813</td>
<td>Congenital shortening of lower limb, bilateral</td>
</tr>
<tr>
<td>Q72891</td>
<td>Other reduction defects of right lower limb</td>
</tr>
<tr>
<td>Q72892</td>
<td>Other reduction defects of left lower limb</td>
</tr>
<tr>
<td>Q72893</td>
<td>Other reduction defects of lower limb, bilateral</td>
</tr>
<tr>
<td>Q7291</td>
<td>Unspecified reduction defect of right lower limb</td>
</tr>
<tr>
<td>Q7292</td>
<td>Unspecified reduction defect of left lower limb</td>
</tr>
<tr>
<td>Q7293</td>
<td>Unspecified reduction defect of lower limb, bilateral</td>
</tr>
<tr>
<td>Q730</td>
<td>Congenital absence of unspecified limb(s)</td>
</tr>
<tr>
<td>Q731</td>
<td>Phocomelia, unspecified limb(s)</td>
</tr>
<tr>
<td>Q738</td>
<td>Other reduction defects of unspecified limb(s)</td>
</tr>
<tr>
<td>Q740</td>
<td>Other congenital malformations of upper limb(s), including shoulder girdle</td>
</tr>
<tr>
<td>Q742</td>
<td>Other congenital malformations of lower limb(s), including pelvic girdle</td>
</tr>
<tr>
<td>Q743</td>
<td>Arthrogryposis multiplex congenita</td>
</tr>
<tr>
<td>Q748</td>
<td>Other specified congenital malformations of limb(s)</td>
</tr>
<tr>
<td>Q749</td>
<td>Unspecified congenital malformation of limb(s)</td>
</tr>
<tr>
<td>Q750</td>
<td>Craniosynostosis</td>
</tr>
<tr>
<td>Q751</td>
<td>Craniofacial dysostosis</td>
</tr>
<tr>
<td>Q752</td>
<td>Hypertelorism</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>Q753</td>
<td>Macrocephaly</td>
</tr>
<tr>
<td>Q754</td>
<td>Mandibulofacial dysostosis</td>
</tr>
<tr>
<td>Q755</td>
<td>Oculomandibular dysostosis</td>
</tr>
<tr>
<td>Q758</td>
<td>Other specified congenital malformations of skull and face bones</td>
</tr>
<tr>
<td>Q759</td>
<td>Congenital malformation of skull and face bones, unspecified</td>
</tr>
<tr>
<td>Q760</td>
<td>Spina bifida occulta</td>
</tr>
<tr>
<td>Q761</td>
<td>Klippel-Feil syndrome</td>
</tr>
<tr>
<td>Q762</td>
<td>Congenital spondylolisthesis</td>
</tr>
<tr>
<td>Q763</td>
<td>Congenital scoliosis due to congenital bony malformation</td>
</tr>
<tr>
<td>Q76411</td>
<td>Congenital kyphosis, occipito-atlanto-axial region</td>
</tr>
<tr>
<td>Q76412</td>
<td>Congenital kyphosis, cervical region</td>
</tr>
<tr>
<td>Q76413</td>
<td>Congenital kyphosis, cervicothoracic region</td>
</tr>
<tr>
<td>Q76414</td>
<td>Congenital kyphosis, thoracic region</td>
</tr>
<tr>
<td>Q76415</td>
<td>Congenital kyphosis, thoracolumbar region</td>
</tr>
<tr>
<td>Q76425</td>
<td>Congenital lordosis, thoracolumbar region</td>
</tr>
<tr>
<td>Q76426</td>
<td>Congenital lordosis, lumbar region</td>
</tr>
<tr>
<td>Q76427</td>
<td>Congenital lordosis, lumbosacral region</td>
</tr>
<tr>
<td>Q76428</td>
<td>Congenital lordosis, sacral and sacrococcygeal region</td>
</tr>
<tr>
<td>Q7649</td>
<td>Other congenital malformations of spine, not associated with scoliosis</td>
</tr>
<tr>
<td>Q765</td>
<td>Cervical rib</td>
</tr>
<tr>
<td>Q766</td>
<td>Other congenital malformations of ribs</td>
</tr>
<tr>
<td>Q767</td>
<td>Congenital malformation of sternum</td>
</tr>
<tr>
<td>Q768</td>
<td>Other congenital malformations of bony thorax</td>
</tr>
<tr>
<td>Q770</td>
<td>Achondrogenesis</td>
</tr>
<tr>
<td>Q771</td>
<td>Thanatophoric short stature</td>
</tr>
<tr>
<td>Q772</td>
<td>Short rib syndrome</td>
</tr>
<tr>
<td>Q774</td>
<td>Achondroplasia</td>
</tr>
<tr>
<td>Q775</td>
<td>Diastrophic dysplasia</td>
</tr>
<tr>
<td>Q776</td>
<td>Chondroectodermal dysplasia</td>
</tr>
<tr>
<td>Q777</td>
<td>Spondyloepiphyseal dysplasia</td>
</tr>
<tr>
<td>Q780</td>
<td>Osteogenesis imperfecta</td>
</tr>
<tr>
<td>Q781</td>
<td>Polyostotic fibrous dysplasia</td>
</tr>
<tr>
<td>Q782</td>
<td>Osteopetrosis</td>
</tr>
<tr>
<td>Q783</td>
<td>Progressive diaphyseal dysplasia</td>
</tr>
<tr>
<td>Q784</td>
<td>Enchondromatosis</td>
</tr>
<tr>
<td>Q788</td>
<td>Other specified osteochondrodysplasias</td>
</tr>
<tr>
<td>Q789</td>
<td>Osteochondrodysplasia, unspecified</td>
</tr>
<tr>
<td>Q790</td>
<td>Congenital diaphragmatic hernia</td>
</tr>
<tr>
<td>Q791</td>
<td>Other congenital malformations of diaphragm</td>
</tr>
<tr>
<td>Q792</td>
<td>Exomphalos</td>
</tr>
<tr>
<td>Q793</td>
<td>Gastrochisis</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q794</td>
<td>Prune belly syndrome</td>
</tr>
<tr>
<td>Q7959</td>
<td>Other congenital malformations of abdominal wall</td>
</tr>
<tr>
<td>Q796</td>
<td>Ehlers-Danlos syndrome</td>
</tr>
<tr>
<td>Q798</td>
<td>Other congenital malformations of musculoskeletal system</td>
</tr>
<tr>
<td>Q799</td>
<td>Congenital malformation of musculoskeletal system, unspecified</td>
</tr>
<tr>
<td>Q800</td>
<td>Ichthyosis vulgaris</td>
</tr>
<tr>
<td>Q801</td>
<td>X-linked ichthyosis</td>
</tr>
<tr>
<td>Q802</td>
<td>Lamellar ichthyosis</td>
</tr>
<tr>
<td>Q803</td>
<td>Congenital bullous ichthyosiform erythroderma</td>
</tr>
<tr>
<td>Q804</td>
<td>Harlequin fetus</td>
</tr>
<tr>
<td>Q808</td>
<td>Other congenital ichthyosis</td>
</tr>
<tr>
<td>Q820</td>
<td>Hereditary lymphedema</td>
</tr>
<tr>
<td>Q821</td>
<td>Xeroderma pigmentosum</td>
</tr>
<tr>
<td>Q822</td>
<td>Mastocytosis</td>
</tr>
<tr>
<td>Q823</td>
<td>Incontinentia pigmenti</td>
</tr>
<tr>
<td>Q824</td>
<td>Ectodermal dysplasia (anhidrotic)</td>
</tr>
<tr>
<td>Q825</td>
<td>Congenital non-neoplastic nevus</td>
</tr>
<tr>
<td>Q826</td>
<td>Congenital sacral dimple</td>
</tr>
<tr>
<td>Q828</td>
<td>Other specified congenital malformations of skin</td>
</tr>
<tr>
<td>Q830</td>
<td>Congenital absence of breast with absent nipple</td>
</tr>
<tr>
<td>Q831</td>
<td>Accessory breast</td>
</tr>
<tr>
<td>Q832</td>
<td>Absent nipple</td>
</tr>
<tr>
<td>Q833</td>
<td>Accessory nipple</td>
</tr>
<tr>
<td>Q838</td>
<td>Other congenital malformations of breast</td>
</tr>
<tr>
<td>Q840</td>
<td>Congenital alopecia</td>
</tr>
<tr>
<td>Q841</td>
<td>Congenital morphological disturbances of hair, not elsewhere classified</td>
</tr>
<tr>
<td>Q842</td>
<td>Other congenital malformations of hair</td>
</tr>
<tr>
<td>Q843</td>
<td>Anonychia</td>
</tr>
<tr>
<td>Q844</td>
<td>Congenital leukonychia</td>
</tr>
<tr>
<td>Q845</td>
<td>Enlarged and hypertrophic nails</td>
</tr>
<tr>
<td>Q846</td>
<td>Other congenital malformations of nails</td>
</tr>
<tr>
<td>Q848</td>
<td>Other specified congenital malformations of integument</td>
</tr>
<tr>
<td>Q849</td>
<td>Congenital malformation of integument, unspecified</td>
</tr>
<tr>
<td>Q8503</td>
<td>Schwannomatosis</td>
</tr>
<tr>
<td>Q851</td>
<td>Tuberous sclerosis</td>
</tr>
<tr>
<td>Q858</td>
<td>Other phakomatoses, not elsewhere classified</td>
</tr>
<tr>
<td>Q859</td>
<td>Phakomatosis, unspecified</td>
</tr>
<tr>
<td>Q870</td>
<td>Congenital malformation syndromes predominantly affecting facial appearance</td>
</tr>
<tr>
<td>Q871</td>
<td>Congenital malformation syndromes predominantly associated with short stature</td>
</tr>
<tr>
<td>Q87410</td>
<td>Marfan's syndrome with aortic dilation</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q87418</td>
<td>Marfan's syndrome with other cardiovascular manifestations</td>
</tr>
<tr>
<td>Q8742</td>
<td>Marfan's syndrome with ocular manifestations</td>
</tr>
<tr>
<td>Q8743</td>
<td>Marfan's syndrome with skeletal manifestation</td>
</tr>
<tr>
<td>Q8782</td>
<td>Arterial tortuosity syndrome</td>
</tr>
<tr>
<td>Q8901</td>
<td>Asplenia (congenital)</td>
</tr>
<tr>
<td>Q8909</td>
<td>Congenital malformations of spleen</td>
</tr>
<tr>
<td>Q891</td>
<td>Congenital malformations of adrenal gland</td>
</tr>
<tr>
<td>Q892</td>
<td>Congenital malformations of other endocrine glands</td>
</tr>
<tr>
<td>Q893</td>
<td>Situs inversus</td>
</tr>
<tr>
<td>Q894</td>
<td>Conjoined twins</td>
</tr>
<tr>
<td>Q897</td>
<td>Multiple congenital malformations, not elsewhere classified</td>
</tr>
<tr>
<td>Q898</td>
<td>Other specified congenital malformations</td>
</tr>
<tr>
<td>Q899</td>
<td>Congenital malformation, unspecified</td>
</tr>
<tr>
<td>Q900</td>
<td>Trisomy 21, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>Q901</td>
<td>Trisomy 21, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>Q902</td>
<td>Trisomy 21, translocation</td>
</tr>
<tr>
<td>Q909</td>
<td>Down syndrome, unspecified</td>
</tr>
<tr>
<td>Q910</td>
<td>Trisomy 18, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>Q911</td>
<td>Trisomy 18, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>Q912</td>
<td>Trisomy 18, translocation</td>
</tr>
<tr>
<td>Q913</td>
<td>Trisomy 18, unspecified</td>
</tr>
<tr>
<td>Q914</td>
<td>Trisomy 13, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>Q915</td>
<td>Trisomy 13, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>Q916</td>
<td>Trisomy 13, translocation</td>
</tr>
<tr>
<td>Q917</td>
<td>Trisomy 13, unspecified</td>
</tr>
<tr>
<td>Q920</td>
<td>Whole chromosome trisomy, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>Q921</td>
<td>Whole chromosome trisomy, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>Q922</td>
<td>Partial trisomy</td>
</tr>
<tr>
<td>Q925</td>
<td>Duplications with other complex rearrangements</td>
</tr>
<tr>
<td>Q9261</td>
<td>Marker chromosomes in normal individual</td>
</tr>
<tr>
<td>Q9262</td>
<td>Marker chromosomes in abnormal individual</td>
</tr>
<tr>
<td>Q927</td>
<td>Triploidy and polyploidy</td>
</tr>
<tr>
<td>Q928</td>
<td>Other specified trisomies and partial trisomies of autosomes</td>
</tr>
<tr>
<td>Q930</td>
<td>Whole chromosome monosomy, nonmosaicism (meiotic nondisjunction)</td>
</tr>
<tr>
<td>Q931</td>
<td>Whole chromosome monosomy, mosaicism (mitotic nondisjunction)</td>
</tr>
<tr>
<td>Q932</td>
<td>Chromosome replaced with ring, dicentric or isochromosome</td>
</tr>
<tr>
<td>Q933</td>
<td>Deletion of short arm of chromosome 4</td>
</tr>
<tr>
<td>Q934</td>
<td>Deletion of short arm of chromosome 5</td>
</tr>
<tr>
<td>Q935</td>
<td>Other deletions of part of a chromosome</td>
</tr>
<tr>
<td>Q937</td>
<td>Deletions with other complex rearrangements</td>
</tr>
<tr>
<td>Q9381</td>
<td>Velo-cardio-facial syndrome</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Q9388</td>
<td>Other microdeletions</td>
</tr>
<tr>
<td>Q9389</td>
<td>Other deletions from the autosomes</td>
</tr>
<tr>
<td>Q950</td>
<td>Balanced translocation and insertion in normal individual</td>
</tr>
<tr>
<td>Q952</td>
<td>Balanced autosomal rearrangement in abnormal individual</td>
</tr>
<tr>
<td>Q958</td>
<td>Other balanced rearrangements and structural markers</td>
</tr>
<tr>
<td>Q960</td>
<td>Karyotype 45, X</td>
</tr>
<tr>
<td>Q961</td>
<td>Karyotype 46, X iso (Xq)</td>
</tr>
<tr>
<td>Q962</td>
<td>Karyotype 46, X with abnormal sex chromosome, except iso (Xq)</td>
</tr>
<tr>
<td>Q963</td>
<td>Mosaicism, 45, X/46, XX or XY</td>
</tr>
<tr>
<td>Q964</td>
<td>Mosaicism, 45, X/other cell line(s) with abnormal sex chromosome</td>
</tr>
<tr>
<td>Q968</td>
<td>Other variants of Turner’s syndrome</td>
</tr>
<tr>
<td>Q969</td>
<td>Turner’s syndrome, unspecified</td>
</tr>
<tr>
<td>Q970</td>
<td>Karyotype 47, XXX</td>
</tr>
<tr>
<td>Q971</td>
<td>Female with more than three X chromosomes</td>
</tr>
<tr>
<td>Q972</td>
<td>Mosaicism, lines with various numbers of X chromosomes</td>
</tr>
<tr>
<td>Q973</td>
<td>Female with 46, XY karyotype</td>
</tr>
<tr>
<td>Q978</td>
<td>Other specified sex chromosome abnormalities, female phenotype</td>
</tr>
<tr>
<td>Q980</td>
<td>Klinefelter syndrome karyotype 47, XXY</td>
</tr>
<tr>
<td>Q981</td>
<td>Klinefelter syndrome, male with more than two X chromosomes</td>
</tr>
<tr>
<td>Q984</td>
<td>Klinefelter syndrome, unspecified</td>
</tr>
<tr>
<td>Q985</td>
<td>Karyotype 47, XYY</td>
</tr>
<tr>
<td>Q986</td>
<td>Male with structurally abnormal sex chromosome</td>
</tr>
<tr>
<td>Q987</td>
<td>Male with sex chromosome mosaicism</td>
</tr>
<tr>
<td>Q988</td>
<td>Other specified sex chromosome abnormalities, male phenotype</td>
</tr>
<tr>
<td>Q990</td>
<td>Chimera 46, XX/46, XY</td>
</tr>
<tr>
<td>Q991</td>
<td>46, XX true hermaphrodite</td>
</tr>
<tr>
<td>Q992</td>
<td>Fragile X chromosome</td>
</tr>
<tr>
<td>Q998</td>
<td>Other specified chromosome abnormalities</td>
</tr>
<tr>
<td>Q999</td>
<td>Chromosomal abnormality, unspecified</td>
</tr>
<tr>
<td>R480</td>
<td>Dyslexia and alexia</td>
</tr>
<tr>
<td>Z31430</td>
<td>Encounter of female for testing for genetic disease carrier status for procreative management</td>
</tr>
<tr>
<td>Z31438</td>
<td>Encounter for other genetic testing of female for procreative management</td>
</tr>
<tr>
<td>Z315</td>
<td>Encounter for genetic counseling</td>
</tr>
<tr>
<td>Z810</td>
<td>Family history of intellectual disabilities</td>
</tr>
<tr>
<td>Z8279</td>
<td>Family history of other congenital malformations, deformations and chromosomal abnormalities</td>
</tr>
<tr>
<td>Z8482</td>
<td>Family history of sudden infant death syndrome</td>
</tr>
<tr>
<td>Z8489</td>
<td>Family history of other specified conditions</td>
</tr>
</tbody>
</table>

### 25.2.5.3 Genetic Testing for Colorectal Cancer
Genetic testing for colorectal cancer is provided to clients that have a known predisposition (having a first-or-second degree relative) to colorectal cancer. Results of the testing may indicate whether the individual has an increased risk of developing colorectal cancer. A first-degree relative is defined as: sibling, parent, or offspring. A second-degree relative is defined as: uncle, aunt, grandparent, nephew, niece, or half-sibling.

Genetic test results, when informative, may influence clinical management decisions. Documentation in the medical record must reflect that the client and/or family member has been given information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions prior to the genetic testing.

Providers must bill the following procedure codes for genetic testing for colorectal cancer:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81201</td>
</tr>
<tr>
<td>81202</td>
</tr>
<tr>
<td>81203</td>
</tr>
<tr>
<td>81210</td>
</tr>
<tr>
<td>81275</td>
</tr>
<tr>
<td>81288</td>
</tr>
<tr>
<td>81292</td>
</tr>
<tr>
<td>81293</td>
</tr>
<tr>
<td>81294</td>
</tr>
<tr>
<td>81295</td>
</tr>
<tr>
<td>81296</td>
</tr>
<tr>
<td>81297</td>
</tr>
<tr>
<td>81298</td>
</tr>
<tr>
<td>81299</td>
</tr>
<tr>
<td>81300</td>
</tr>
<tr>
<td>81301</td>
</tr>
<tr>
<td>81317</td>
</tr>
<tr>
<td>81318</td>
</tr>
<tr>
<td>81319</td>
</tr>
<tr>
<td>81327</td>
</tr>
</tbody>
</table>

The provider must order the most appropriate test based on familial medical history and the availability of previous family testing results. Interpretation of gene mutation analysis results is not separately reimbursable. Interpretation is part of the Physical Evaluation and Management (E/M service).

Genetic testing for colorectal cancer is limited to once per lifetime. Additional tests will not be authorized.

Authorization Requirements
Prior authorization is required for genetic testing for colorectal cancer.

A completed CSHCN Services Program Authorization and Prior Authorization Request form, signed and dated by the referring providers, must be submitted:

- Any provider’s signature, including the prescribing provider’s, on a submitted document indicates the provider certifies, to the best of the provider’s knowledge, the information in the document is true, accurate and complete.
- All documentation submitted with a provider’s signature must have a date next to the signature and must be kept in the client’s medical record.
- Stamped signatures will not be accepted.

To facilitate a determination of medical necessity and avoid unnecessary denials, the physician must provide correct and complete information, including accurate medical necessity of the services requested. The client’s medical record must include documentation of formal pre-test counseling, including assessment of the client’s ability to understand the risks and limitations of the test, and the client’s informed choice to proceed with the genetic testing for colorectal cancer. The medical record is subject to retrospective review.

Requisition forms from the laboratory are not sufficient documentation for verification of the personal and family history. Medical documentations submitted by the physician must verify the client’s diagnosis or family history.

Familial Adenomatous Polyposis (FAP)

Prior authorization for testing Familial Adenomatous Polyposis (FAP) (procedure codes 81201, 81202, and 81203) may be offered to individuals who have well defined hereditary cancer syndromes and for which either a positive or negative result will change medical care.

Documentation must include one of the following:
- Client with greater than 20 polyps.
- Client with a first-degree relative with FAP and a documented mutation.
- Clients who are seven years of age or younger must have rationale for testing and documentation of medical necessity included in the client’s medical record and submitted with the prior authorization request.
Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

The following procedure codes require prior authorization for testing Hereditary Nonpolyposis Colorectal Cancer (HNPCC) to determine whether an individual has an increased risk for colorectal cancer or other HNPCC-associated cancers, including Lynch Syndrome:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81292</td>
</tr>
<tr>
<td>81297</td>
</tr>
<tr>
<td>81317</td>
</tr>
</tbody>
</table>

Results of the test may influence clinical management decisions. Documentation of medical necessity must include one of the following:

- Client has three or more family members (one of whom is a first-degree relative) with colorectal cancer and two successive generations are affected and one or more of the colorectal cancers were diagnosed at 50 years of age or younger and FAP has been ruled out.
- A client has had two HNPCC cancers.
- A client has colorectal cancer and a first-degree relative with either colorectal cancer or HNPCC extracolonic cancer at 50 years of age or younger.
- A client has had colorectal cancer or endometrial cancer at 50 years of age or younger.
- A client has had right-sided colorectal cancer with an undifferentiated pattern or histology at 50 years of age or younger.
- A client has had signet-cell type colorectal cancer at 50 years of age or younger.
- A client has had colorectal adenoma at 40 years of age or younger.
- A client is an asymptomatic individual with a first or second-degree relative with a documented HNPCC mutation.
- A client has a family history of malignant neoplasm in the gastrointestinal tract.

Clients who are twenty years of age or younger must have a clear rationale for testing and documentation of medical necessity from the client’s record must be submitted with the prior authorization request.

25.2.5.4 Genetic Testing for Hereditary Breast and Ovarian Cancers

Genetic testing for hereditary breast and ovarian cancers is provided to clients who are at least 18 years of age with an inherited increased risk (having a first-, second- or third-degree relative) for developing breast and certain other cancers.

Genetic testing of mutations in BRCA1 and BRCA2, the genes associated with hereditary breast and ovarian cancer, is based on the National Comprehensive Cancer Network (NCCN) guidelines. These guidelines highly recommend genetic counseling to clients when genetic testing is offered and after test results are disclosed.

Genetic test results, when informative, may influence clinical management decisions. Documentation in the medical record must reflect that the client and/or family member has been given information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions prior to the genetic testing.

Providers must bill the following procedure codes genetic testing for hereditary breast and ovarian cancers:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81162</td>
</tr>
<tr>
<td>81215</td>
</tr>
</tbody>
</table>
The provider must order the most appropriate test based on familial medical history and the availability of previous family testing results only if the test results will affect treatment decisions or provide prognostic information. Interpretation of genetic testing results is not separately reimbursable. Interpretation is part of the physician evaluation and management (E/M) service.

BRCA uncommon, large rearrangement testing (procedure code 81213) may be considered for reimbursement with submission of the following evidence:

- The client is at an exceptionally high risk for hereditary breast or ovarian cancers, and
- The client has undergone comprehensive, full sequence analysis of both BRCA1 and BRCA2 and the results of the test (procedure code 81211) are negative.

Genetic testing for hereditary breast and ovarian cancers is limited to once per lifetime. Additional tests will not be authorized.

Genetic testing for hereditary breast and ovarian cancer predisposition is not covered as a screening test in the general population.

**Authorization Requirements**

Prior authorization is not required for uncommon, large rearrangement testing of the BRCA1 and BRCA2 genes (procedure code 81213) when submitted with a negative test result for procedure code 81211.

Prior authorization is required for all other BRCA1/BRCA2 genetic testing for susceptibility to breast and ovarian cancer.

A completed CSHCN Services Program Genetic Testing for Hereditary Breast and Ovarian Cancers Prior Authorization Request form, signed and dated by the ordering practitioner, must be submitted and approved prior to the date of service. The form must include:

- The physician’s signature on a submitted document that indicates that the physician certifies, to the best of the physician’s knowledge, the information in the document is true, accurate, and complete.
- All documentation must be submitted with a physician’s signature with a date next to the signature and must be kept in the client’s medical record.
- No stamped signatures will be accepted.

To facilitate a determination of medical necessity and avoid unnecessary denials, the physician must provide correct and complete information, including accurate medical necessity of the service(s) requested. Documentation supporting the medical need for genetic testing of hereditary breast and ovarian cancers must include:

- The client’s diagnosis and prognosis, including the age of onset and the specific location of cancer
- The client’s family history, if applicable, including the specifics about the relationship to the client, cancer site, and the age of cancer diagnosis
- The NCCN criterion met supporting the need for the specific test requested
- Documentation of how the result of the test will directly impact the plan of treatment delivered to the client.

Requisition forms from the laboratory are not sufficient documentation for verification of the personal and family history.

To complete the prior authorization process, the provider must complete and submit the prior authorization request and required documentation to the TMHP CSHCN Services Program Authorization Department.

If the service is medically necessary and is provided after hours or on a recognized holiday or weekend, the service may be authorized when the request is submitted on the next business day. A completed CSHCN Services Program Genetic Testing for Hereditary Breast and Ovarian Cancers Prior Authorization Request form and supporting documentation must be received within these deadlines for prior authorization to be considered. Extensions to these deadlines are not given by the CSHCN Services Program for providers to correct incomplete PA requests.
The client’s medical record must include a copy of the prior authorization request, all submitted documentation, and an assessment of the client’s ability to understand the risks and limitations of the test as well as the client’s informed choice to proceed with the genetic testing. The medical record is subject to retrospective review.

25.2.6 Cytopathology of Vaginal, Cervical, and Uterine Sites

Because of the technical nature of processing and interpreting a Pap smear or specimen for cytopathology, pathologists are the only physician specialty reimbursed with the following exception:

**Exception:** Other physician specialties equipped to perform Pap smears in their offices must have modifier SU on the claim form.

Procurement and handling of the Pap smear or specimen for cytopathology is considered part of the evaluation and management of the client and is not reimbursed separately.

A pathologist must report the place of service (POS) according to where the Pap smear is interpreted: office (POS 1), inpatient (POS 3), outpatient (POS 5), or independent laboratory (POS 6).

The following procedure codes are payable for gynecological cytopathology services and may be reimbursed only to pathologists and CLIA-certified laboratories whose directors providing technical supervision of cytopathology services are pathologists:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>88142</td>
</tr>
<tr>
<td>88152</td>
</tr>
<tr>
<td>88165</td>
</tr>
</tbody>
</table>

Procedure code 88155 is an add-on code to be used in conjunction with the following cytopathology procedure codes:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>88142</td>
</tr>
<tr>
<td>88152</td>
</tr>
<tr>
<td>88166</td>
</tr>
</tbody>
</table>

The interpretation portion of any gynecological cytopathology test must be reported using only procedure code 88141 and type of service “I.” Reimbursement is restricted to laboratories and pathologists. The interpretation portion may be reimbursed in addition to the following cytopathology procedure codes:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>88142</td>
</tr>
<tr>
<td>88152</td>
</tr>
<tr>
<td>88166</td>
</tr>
</tbody>
</table>

25.2.7 Cytopathology Studies Other Than Vaginal, Cervical, or Uterine

Procurement and handling of the specimen is not reimbursed separately for cytopathology of sites other than vaginal, cervical, or uterine and is considered part of the evaluation and management of the client. These procedures may be reimbursed according to the POS where the cytopathology smear is interpreted.

Procedure codes 88160, 88161, and 88162 are payable for the total component and technical component in the office (place of service [POS] 1), outpatient setting (POS 5), or independent laboratory (POS 6). Procedure codes 88160, 88161, and 88162 are payable for the interpretation in the inpatient (POS 3) or outpatient (POS 5) settings.

Procedure codes 88160, 88161, and 88162 are payable to a pathologist for the interpretation in the inpatient hospital (POS 3) and outpatient (POS 5) settings.
Procedure codes 88160 or 88161 total components and interpretations are denied as part of the total component and interpretation for procedure code 88162.

Procedure code 88160 total component and interpretation is denied as part of the total component and interpretation for procedure code 88161.

Reimbursement for the total component or interpretation and technical component for procedure codes 88160, 88161, and 88162 is limited to pathologists (doctor of medicine [MD] and doctor of osteopathy [DO]) and laboratories (CLIA-certified to provide pathology services).

### 25.2.8 Evocative and Suppression Testing

Evocative and suppression testing is a benefit when billed for the total component. Providers must bill the following procedure codes for evocative suppression testing:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>80400 80402 80406 80408 80410 80412 80414 80415</td>
</tr>
<tr>
<td>80416 80417 80418 80420 80422 80424 80426 80428</td>
</tr>
<tr>
<td>80430 80432 80434 80435 80436 80438 80439</td>
</tr>
</tbody>
</table>

### 25.2.9 Helicobacter pylori (H. pylori)

H. pylori testing is a benefit. Serology testing for H. pylori is a noninvasive diagnostic procedure preferred for initial diagnosis but is not indicated once a diagnosis is made.

H. pylori testing is not indicated or a benefit for any of the following:

- New onset uncomplicated dyspepsia
- New onset dyspepsia that is responsive to conservative treatment (e.g., withdrawal of nonsteroidal anti-inflammatory drugs [NSAIDs] or use of antisecretory agents) (If conservative treatment does not eliminate the symptoms, further testing may be indicated to determine the presence of H. pylori.)
- Screening for H. pylori in asymptomatic clients
- Dyspeptic clients who require endoscopy and biopsy
- A negative endoscopy in the previous 90 days
- A planned endoscopy
- New onset H. pylori that is still being treated

Serology testing is not indicated or a benefit for monitoring response to therapy. The following procedure codes may be reimbursed by the CSHCN Services Program:

- Serology testing, procedure codes 83009 and 86677
- Stool testing, procedure code 87338
- Breath testing, procedure codes 78267, 78268, 83013, and 83014

These procedure codes are considered a clinical lab service and must be billed using type of service (TOS) 5. The interpretation/professional component TOS I is not separately reimbursed.

H. pylori testing may be indicated for symptomatic clients with a documented history of chronic or recurrent duodenal ulcers, gastric ulcers, or chronic gastritis. The history should delineate the failed conservative treatment for the condition.

Only one of the following procedure codes may be reimbursed once per lifetime when billed by any provider: 83009 or 86677. A second test may be considered on appeal with documentation submitted indicating the original test result was negative for H. pylori.

If a follow-up breath or stool test is used to document the eradication of H. pylori, the medical record should contain evidence of one of the following:

- The patient remains symptomatic after a treatment regimen for H. pylori.
• The patient is asymptomatic after H. pylori eradication therapy but has a history of hemorrhage, perforation, or outlet obstruction from peptic ulcer disease.

• The patient has a history of ulcer on chronic nonsteroidal anti-inflammatory drug (NSAID) or anticoagulant therapy.

Providers cannot be reimbursed for testing for the eradication of H. pylori, procedure codes 78267, 78268, 83013, 83014, and 87338 within 35 days of the initial test.

H. pylori testing will be denied if it is performed within 90 days of the following procedure codes:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>43200 43201 43202 43216 43217 43228 43231 43232 43234 43235</td>
</tr>
<tr>
<td>43236 43237 43238 43239 43241 43242 43250 43251 43257 43258</td>
</tr>
<tr>
<td>43259</td>
</tr>
</tbody>
</table>

Procedure codes 78267, 78268, 83013, 83014, and 87338 may be reimbursed within 90 days of the procedure codes in the preceding table if the provider submits documentation that indicates the client was tested for eradication after treatment.

### 25.2.10 Hematology and Coagulation

The following hematology and coagulation procedure codes are benefits of the CSHCN Services Program:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>85002 85004 85007 85008 85009 85013 85014* 85018* 85025 85027</td>
</tr>
<tr>
<td>85032 85041 85044 85045 85046 85048 85049 85055 85060 85097</td>
</tr>
<tr>
<td>85130 85170 85175 85210 85220 85230 85240 85244 85245 85246</td>
</tr>
<tr>
<td>85247 85250 85260 85270 85280 85290 85291 85292 85293 85300</td>
</tr>
<tr>
<td>85301 85302 85303 85305 85306 85307 85335 85337 85345 85347</td>
</tr>
<tr>
<td>85348 85360 85362 85366 85370 85378 85379 85380 85384 85385</td>
</tr>
<tr>
<td>85390 85396 85397 85400 85410 85415 85420 85421 85441 85445</td>
</tr>
<tr>
<td>85475 85520 85525 85530 85536 85540 85547 85549 85555 85557</td>
</tr>
<tr>
<td>85576* 85597 85598 85610* 85611 85612 85613 85635 85651 85652</td>
</tr>
<tr>
<td>85660 85670 85675 85705 85730 85732 85810 85999 G0306 G0307</td>
</tr>
</tbody>
</table>

* CLIA Waived test

The following procedure codes may be reimbursed once per day by the same provider:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>85027 85347 85397 85520 85576 85610 85730</td>
</tr>
</tbody>
</table>

Procedure code 85027 will deny if billed on the same date of service by the same provider as procedure codes 85007 and 85009.

Procedure code 85660 may be reimbursed once per lifetime by any provider. An additional test may be considered on appeal with documentation indicating the provider was unaware the client was tested previously or was unable to obtain the client’s medical records.
25.2.11 Microbiology

The following microbiology procedure codes are benefits of the CSHCN Services Program:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>87003</td>
</tr>
<tr>
<td>87077*</td>
</tr>
<tr>
<td>87109</td>
</tr>
<tr>
<td>87153</td>
</tr>
<tr>
<td>87184</td>
</tr>
<tr>
<td>87209</td>
</tr>
<tr>
<td>87265</td>
</tr>
<tr>
<td>87277</td>
</tr>
<tr>
<td>87301</td>
</tr>
<tr>
<td>87337</td>
</tr>
<tr>
<td>87391</td>
</tr>
<tr>
<td>87471</td>
</tr>
<tr>
<td>87487</td>
</tr>
<tr>
<td>87501</td>
</tr>
<tr>
<td>87516</td>
</tr>
<tr>
<td>87530</td>
</tr>
<tr>
<td>87540</td>
</tr>
<tr>
<td>87561</td>
</tr>
<tr>
<td>87625</td>
</tr>
<tr>
<td>87660</td>
</tr>
<tr>
<td>87806*</td>
</tr>
<tr>
<td>87902</td>
</tr>
</tbody>
</table>

* CLIA Waived test
+ Add-on code

Note: The procedure codes above do not require prior authorization.

25.2.12 Human Immunodeficiency Virus (HIV) Drug Resistance Testing

Standard treatment regimens for HIV therapy require a combination of three or more drugs. Standard therapy continues if a reduction in viral load is achieved. Incomplete virus suppression favors the development of a drug resistance and jeopardizes the success of future therapy. Testing for drug resistance as a prerequisite to further therapy is indicated under such circumstances.

To ensure accurate testing results, the client must be on appropriate antiretroviral therapy at the same time of testing or have discontinued the drug regimen within the past four weeks.

Testing for antiretroviral drug resistance is indicated in certain clinical situations. These indications include any of the following:

- Individuals who have an initial (new onset) acute HIV infection, to determine if a drug-resistant viral strain was transmitted, and to plan a drug regimen accordingly; or
- Individuals who have virological failure during antiretroviral therapy, laboratory results showing HIV RNA levels greater than 500, and less than 1000 copies/ml.
Documentation must be maintained in the client’s medical record to support medical necessity for drug-resistance testing. Specific documentation requirements are dependent upon testing rationale. Documentation must include, but is not limited to, the date the drug regimen was initiated, the dosage and frequency of the prescribed medication, and laboratory tests which support all of the following:

- Acute HIV infection, with identification of the specific viral strain; and
- Virological failure during antiretroviral therapy with HIV RNA levels greater than 500 and less than 1000 copies/ml.

Drug resistance testing is not recommended if one of the following criteria is met:

- The drug regimen has been discontinued for more than four weeks; or
- The viral load is less than 500 copies/ml.

25.2.13 Organ or Disease-Oriented Panels

The following organ or disease-oriented panel procedure codes are benefits of the CSHCN Services Program:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>80047</td>
</tr>
</tbody>
</table>

For all procedure codes listed in the organ or disease-oriented panels table above, refer to the Current Procedural Terminology (CPT) manual for information regarding laboratory panels and appropriate modifiers.

Reimbursement for the complete panel procedure code represents the total payment for all automated laboratory tests that are covered under that panel combined with any other automated tests that are billed for the client for the same date of service. Reimbursement for the individual components of the complete laboratory panel will not exceed the automated test panel (ATP) fee for the total number of automated tests that are billed for the client for the same date of service.

When all of the components of the panel are performed, the complete panel procedure code must be billed. When only two or more components of the panel are performed, the individual procedure codes for each laboratory test performed may be billed.

25.2.14 Urinalysis and Chemistry

The following urinalysis and chemistry procedure codes are benefits of the CSHCN Services Program:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81000</td>
</tr>
<tr>
<td>82009</td>
</tr>
<tr>
<td>82044*</td>
</tr>
<tr>
<td>82120*</td>
</tr>
<tr>
<td>82157</td>
</tr>
<tr>
<td>82240</td>
</tr>
<tr>
<td>82300</td>
</tr>
<tr>
<td>82370</td>
</tr>
<tr>
<td>82384</td>
</tr>
<tr>
<td>82480</td>
</tr>
<tr>
<td>82540</td>
</tr>
</tbody>
</table>
Procedure codes 81099, 82105, 82107, 82803, 82805, 82948, 84703, and 84999 are limited to one per day when billed by any provider.

Procedure code 84583 will be denied if billed on the same day by the same provider as procedure codes 81000, 81001, 81002, 81003, 81005, or 81020.

Procedure code 82270 is limited to one per rolling year when billed by any provider.

Procedure code 83698 is limited to two per rolling year when billed by any provider. Claims submitted for procedure code 83698 that are in excess of two per year may be considered on appeal with documentation of any of the following:

- Medical necessity for the additional test.

Molecular Testing

83006

Ophthalmology and Optometry

83861*

* CLIA Waived test
+ Add-on code
The provider was unable to obtain the previous records from a different provider.

The provider was new to treating the client and was not aware the client had received the test.

Refer to: Chapter 25.2.9, “Helicobacter pylori (H. pylori),” on page 25-34 for information about limitations on procedure codes 83009, 83013, and 83014.

25.2.15 Other Laboratory Services
Laboratory and interpretation procedure codes 86077, 86078, and 86079 should be used when blood bank physician services are needed.

The following procedure codes are denied for pathologists as noncovered for specialty type:

<table>
<thead>
<tr>
<th>Procedure Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgery</strong></td>
</tr>
<tr>
<td>36430 36440 36455</td>
</tr>
<tr>
<td><strong>Consultation</strong></td>
</tr>
<tr>
<td>99251 99252 99253 99254 99255</td>
</tr>
</tbody>
</table>

Payment may be considered on appeal if the pathologist can document the medical necessity of performing the procedures.

25.2.16 Repeated Procedures

25.2.16.1 Modifier 91
Modifier 91 must be used for clinical diagnostic laboratory tests performed more than one time per day as follows:

- Modifier 91 must not be used when billing the initial procedure. It must be used to indicate the repeated procedure.
- If more than two services are billed on the same day by the same provider regardless of the use of modifier 91, the claim or detail is denied.
- If a repeated procedure performed by the same provider on the same day is billed without modifier 91, it is denied as a duplicate procedure.
- If a claim is denied for a quantity more than two or as a duplicate procedure, the times of these procedures must be documented on the appeal.
- Modifier 91 is not required and must not be used when billing multiple quantities of a supply (for example, disposable diapers or sterile saline).

Certain procedure codes have been removed from modifier 91 auditing. These are procedure codes that have been identified as routinely being performed at the same time, more than twice per day for each analyte. Documentation of time is required. If no time documentation is received, the claim will be denied. Providers may appeal claims that have been denied for documentation of time. Most procedure codes initially requiring modifier 91 continue to be audited for modifier 91.

When appealing claims with modifier 91 for repeat procedures, providers must separate the details. One detail should be appealed without the modifier and one detail with the modifier including documentation of times for each repeated procedure.

Refer to: Chapter 7, “Appeals and Administrative Review,” on page 7-1.

25.2.17 Receiving Labs and Lab Handling Fees
An independent laboratory may not bill for laboratory tests when the specimen is forwarded to another laboratory without performing any tests on that specimen. An independent laboratory may bill the CSHCN Services Program for tests referred to another laboratory (independent or hospital) only if the independent laboratory performs at least one test and forwards a portion of
the same specimen to another laboratory (receiving laboratory) to have one or more tests performed. In this instance, the receiving laboratory may bill for tests it performs and all tests the receiving laboratory performs on the specimen. When billing, the YES box in Block 20 of the CMS-1500 paper claim form must be marked, the complete name, provider identifier, address, and ZIP code of the outside receiving laboratory where the specimen was forwarded must be entered in Block 32, and the TPI of the receiving laboratory must be indicated in Block 24j next to each procedure to be performed by the receiving laboratory. Enter the TPI in the shaded area of the field. Enter the NPI in the unshaded area of the field.

Only one handling fee may be charged per day, per client, unless specimens are sent to two or more different laboratories.

In order to bill a handling fee, the receiving laboratory’s name and address and unique TPI number must be included on the claim in Blocks 17 and 17B.

In both situations, if a specimen is collected by venipuncture or catheterization, an independent laboratory that forwards a specimen to another laboratory (independent or hospital) may bill a handling fee (procedure code 99001) for collecting and forwarding the specimen to the other laboratory.

When billing for laboratory services, providers should use the date the specimen is collected as the date of service. If the specimen is sent to a receiving laboratory and the client is an inpatient, the hospital is responsible for payment of these services to the receiving laboratory.

### 25.3 Claims Information

Independent laboratory services must be submitted to TMHP in an approved electronic format or on the CMS-1500 paper claim form. Providers may purchase CMS-1500 paper claim forms from the vendor of their choice. TMHP does not supply the forms.

When completing a CMS-1500 paper claim form, all required information must be included on the claim, as information is not keyed from attachments. Superbills or itemized statements are not accepted as claim supplements.

Laboratory services providers must indicate the specific laboratory procedure codes that are being submitted for claims filing.

The Healthcare Common Procedure Coding System (HCPCS)/CPT codes included in policy are subject to National Correct Coding Initiative (NCCI) relationships. Exceptions to NCCI code relationships that may be not in CSHCN Services Program medical policy are no longer valid. Providers should refer to the CMS NCCI web page for correct coding guidelines and specific applicable code combinations. In instances when CSHCN Services Program medical policy quantity limitations are more restrictive than NCCI Medically Unlikely Edits (MUE) guidance, medical policy prevails.

Refer to: Chapter 40, “TMHP Electronic Data Interchange (EDI),” on page 40-1 for information about electronic claims submissions.


Chapter 5, “CMS-1500 Paper Claim Form Instructions,” on page 5-25 for instructions on completing paper claims. Blocks that are not referenced are not required for processing by TMHP and may be left blank.

### 25.3.1 Modifiers To Use When Billing Laboratory Procedures

Providers may use an appropriate modifier to bill for laboratory procedures as needed. Providers may refer to the CMS website at www.cms.gov for guidelines on which modifier to use when submitting claims for laboratory services.
25.4 Reimbursement

In compliance with state and federal law, the CSHCN Services Program reimburses laboratories for most services according to maximum fees established by federal law, Medicare, or HHSC. Clinical laboratory services may be reimbursed the lower of the national fee schedule amount, the billed amount, or the amount allowed by Texas Medicaid. Some services (e.g., anatomical pathology) may be reimbursed according to the Texas Medicaid Reimbursement Methodology (TMRM). For automated lab tests, the fees that are paid are calculated by compiling the number of automated tests on the date of service and assigning an automated test panel payment code.

Physicians may be reimbursed for laboratory services the lower of the billed amount or the amount allowed by Texas Medicaid. Outpatient hospitals may be reimbursed for laboratory services at 72 percent of the rate equivalent to the hospital’s Medicaid interim rate.

As the result of the Tax Equity and Fiscal Responsibility Act (TEFRA) of 1982, independent laboratories are not directly reimbursed by the CSHCN Services Program when providing tests to clients registered as hospital inpatients or hospital outpatients. Reimbursement must be obtained from the hospital. These services cannot be billed to the client.

For fee information, providers can refer to the Online Fee Lookup (OFL) on the TMHP website at www.tmhp.com.

The CSHCN Services Program implemented rate reductions for certain services. The OFL includes a column titled “Adjusted Fee” to display the individual fees with all percentage reductions applied. Additional information about rate changes is available on the TMHP website at www.tmhp.com/pages/topics/rates.aspx.

Note: Certain rate reductions including, but not limited to, reductions by place of service, client type program, or provider specialty may not be reflected in the Adjusted Fee column.

25.4.1 Clinical Laboratory Fee Schedule

The Deficit Reduction Act (DEFRA) of 1984 requires clinical diagnostic laboratory tests that are performed in a physician’s office by an independent laboratory or a hospital laboratory for its outpatients be reimbursed on the basis of maximum fee schedules. The Texas Medicare carrier publishes the fee schedules on an annual basis. By federal law, the CSHCN Services Program payment cannot exceed that allowed by Medicare.

25.4.2 One-day Payment Window Reimbursement Guidelines

According to the one-day payment window reimbursement guidelines, most professional and outpatient diagnostic and nondiagnostic services that are rendered within 1 day of an inpatient hospital stay and are related to the inpatient hospital admission will not be reimbursed separately from the inpatient hospital stay if the services are rendered by the hospital or an entity that is wholly owned or operated by the hospital.

The one-day payment window reimbursement guidelines do not apply for professional services that are rendered in the inpatient hospital setting.

Refer to: Section 24.3.7, “Payment Window Reimbursement Guidelines,” on page 24-13 for additional information about the one-day payment window reimbursement guidelines.

25.5 TMHP-CSHCN Services Program Contact Center

The TMHP-CSHCN Services Program Contact Center at 1-800-568-2413 is available Monday through Friday from 7 a.m. to 7 p.m., Central Time, and is the main point of contact for the CSHCN Services Program provider community.